drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.69k
| drug2_id
int64 0
1.69k
| drug_pair
listlengths 2
2
| drug1_name
stringlengths 4
85
| drug2_name
stringlengths 4
85
| drug1_desc
stringlengths 27
1.09k
| drug2_desc
stringlengths 27
6.14k
| label
stringclasses 3
values | label_idx
int64 0
2
| all_paths
listlengths 1
10
| all_paths_str
listlengths 1
10
| path_str
stringlengths 0
3.57k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00224
|
DB00451
| 215
| 542
|
[
"DDInter917",
"DDInter1064"
] |
Indinavir
|
Levothyroxine
|
A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem]
|
Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T<sub>4</sub> (tetraiodothyronine or thyroxine) and T<sub>3</sub> (triiodothyronine or ), resulting in diminished down-stream effects of these hormones. Without sufficient quantities of circulating thyroid hormones, symptoms of hypothyroidism begin to develop such as fatigue, increased heart rate, depression, dry skin and hair, muscle cramps, constipation, weight gain, memory impairment, and poor tolerance to cold temperatures.[F4636,A35722] In response to Thyroid Stimulating Hormone (TSH) release by the pituitary gland, a normally functioning thyroid gland will produce and secrete T<sub>4</sub>, which is then converted through deiodination (by type I or type II 5′-deiodinases) into its active metabolite T<sub>3</sub>. While T<sub>4</sub> is the major product secreted by the thyroid gland, T<sub>3</sub> exerts the majority of the physiological effects of the thyroid hormones; T<sub>4</sub> and T<sub>3</sub> have a relative potency of ~1:4 (T4:T3). T<sub>4</sub> and T<sub>3</sub> act on nearly every cell of the body, but have a particularly strong effect on the cardiac system. As a result, many cardiac functions including heart rate, cardiac output, and systemic vascular resistance are closely linked to thyroid status. Prior to the development of levothyroxine, or desiccated thyroid, used to be the mainstay of treatment for hypothyroidism. However, this is no longer recommended for the majority of patients due to several clinical concerns including limited controlled trials supporting its use. Desiccated thyroid products contain a ratio of T4 to T3 of 4.2:1, which is significantly lower than the 14:1 ratio of secretion by the human thyroid gland. This higher proportion of T3 in desiccated thyroid products can lead to supraphysiologic levels of T3 which may put patients at risk of thyrotoxicosis if thyroid extract therapy is not adjusted according to the serum TSH.[A35722, F4636]
|
Moderate
| 1
|
[
[
[
215,
24,
542
]
],
[
[
215,
6,
15333
],
[
15333,
45,
542
]
],
[
[
215,
18,
10375
],
[
10375,
57,
542
]
],
[
[
215,
21,
29291
],
[
29291,
60,
542
]
],
[
[
215,
25,
467
],
[
467,
62,
542
]
],
[
[
215,
24,
1144
],
[
1144,
63,
542
]
],
[
[
215,
24,
590
],
[
590,
24,
542
]
],
[
[
215,
63,
1179
],
[
1179,
24,
542
]
],
[
[
215,
6,
15333
],
[
15333,
45,
1294
],
[
1294,
1,
542
]
],
[
[
215,
6,
8374
],
[
8374,
45,
752
],
[
752,
62,
542
]
]
] |
[
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
]
],
[
[
"Indinavir",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B1"
],
[
"SLCO1B1",
"{u} (Gene) is bound by {v} (Compound)",
"Levothyroxine"
]
],
[
[
"Indinavir",
"{u} (Compound) downregulates {v} (Gene)",
"RPS4Y1"
],
[
"RPS4Y1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Levothyroxine"
]
],
[
[
"Indinavir",
"{u} (Compound) causes {v} (Side Effect)",
"Muscular weakness"
],
[
"Muscular weakness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Levothyroxine"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levothyroxine"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
]
],
[
[
"Indinavir",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B1"
],
[
"SLCO1B1",
"{u} (Gene) is bound by {v} (Compound)",
"Dextrothyroxine"
],
[
"Dextrothyroxine",
"{u} (Compound) resembles {v} (Compound)",
"Levothyroxine"
]
],
[
[
"Indinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levothyroxine"
]
]
] |
Indinavir (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Levothyroxine (Compound)
Indinavir (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Levothyroxine (Compound)
Indinavir (Compound) causes Muscular weakness (Side Effect) and Muscular weakness (Side Effect) is caused by Levothyroxine (Compound)
Indinavir may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Levothyroxine
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine
Indinavir (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Dextrothyroxine (Compound) and Dextrothyroxine (Compound) resembles Levothyroxine (Compound)
Indinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cimetidine (Compound) and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Levothyroxine
|
DB00883
|
DB00907
| 426
| 290
|
[
"DDInter989",
"DDInter427"
] |
Isosorbide dinitrate
|
Cocaine (topical)
|
A vasodilator used in the treatment of angina pectoris. Its actions are similar to nitroglycerin but with a slower onset of action.
|
Cocaine can cause developmental toxicity and female reproductive toxicity according to an independent committee of scientific and health experts.
|
Moderate
| 1
|
[
[
[
426,
24,
290
]
],
[
[
426,
6,
8374
],
[
8374,
45,
290
]
],
[
[
426,
21,
28658
],
[
28658,
60,
290
]
],
[
[
426,
40,
1107
],
[
1107,
63,
290
]
],
[
[
426,
24,
1053
],
[
1053,
64,
290
]
],
[
[
426,
6,
8374
],
[
8374,
45,
1622
],
[
1622,
24,
290
]
],
[
[
426,
21,
28658
],
[
28658,
60,
85
],
[
85,
1,
290
]
],
[
[
426,
40,
1107
],
[
1107,
6,
8374
],
[
8374,
45,
290
]
],
[
[
426,
6,
8238
],
[
8238,
45,
1637
],
[
1637,
63,
290
]
],
[
[
426,
24,
1053
],
[
1053,
21,
28681
],
[
28681,
60,
290
]
]
] |
[
[
[
"Isosorbide dinitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cocaine"
]
],
[
[
"Isosorbide dinitrate",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cocaine"
]
],
[
[
"Isosorbide dinitrate",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cocaine"
]
],
[
[
"Isosorbide dinitrate",
"{u} (Compound) resembles {v} (Compound)",
"Isosorbide mononitrate"
],
[
"Isosorbide mononitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cocaine"
]
],
[
[
"Isosorbide dinitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cocaine"
]
],
[
[
"Isosorbide dinitrate",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Voriconazole"
],
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cocaine"
]
],
[
[
"Isosorbide dinitrate",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Atropine"
],
[
"Atropine",
"{u} (Compound) resembles {v} (Compound)",
"Cocaine"
]
],
[
[
"Isosorbide dinitrate",
"{u} (Compound) resembles {v} (Compound)",
"Isosorbide mononitrate"
],
[
"Isosorbide mononitrate",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cocaine"
]
],
[
[
"Isosorbide dinitrate",
"{u} (Compound) binds {v} (Gene)",
"NPR1"
],
[
"NPR1",
"{u} (Gene) is bound by {v} (Compound)",
"Amyl Nitrite"
],
[
"Amyl Nitrite",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cocaine"
]
],
[
[
"Isosorbide dinitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cocaine"
]
]
] |
Isosorbide dinitrate may cause a moderate interaction that could exacerbate diseases when taken with Cocaine
Isosorbide dinitrate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cocaine (Compound)
Isosorbide dinitrate (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Cocaine (Compound)
Isosorbide dinitrate (Compound) resembles Isosorbide mononitrate (Compound) and Isosorbide mononitrate may cause a moderate interaction that could exacerbate diseases when taken with Cocaine
Isosorbide dinitrate may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Cocaine
Isosorbide dinitrate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Voriconazole (Compound) and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Cocaine
Isosorbide dinitrate (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Atropine (Compound) and Atropine (Compound) resembles Cocaine (Compound)
Isosorbide dinitrate (Compound) resembles Isosorbide mononitrate (Compound) and Isosorbide mononitrate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cocaine (Compound)
Isosorbide dinitrate (Compound) binds NPR1 (Gene) and NPR1 (Gene) is bound by Amyl Nitrite (Compound) and Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Cocaine
Isosorbide dinitrate may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Cocaine (Compound)
|
DB00375
|
DB01070
| 1,037
| 1,098
|
[
"DDInter433",
"DDInter558"
] |
Colestipol
|
Dihydrotachysterol
|
Bile acid sequestrants like colestipol have been in use since the 1970s.[FDA Label, F4555, F4567, L6262] And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia, colestipol is still generally only employed as an adjunct therapy and the relatively physical nature of its pharmacological activity sometimes limits its usefulness.[FDA Label, F4555, F4567, L6262] In particular, as colestipol's general mechanism of action ultimately results in the decreased absorption and enhanced secretion of bile acids and lipids in the feces, patients who take complicated medication regimens, experience constipation or biliary obstruction, etc. may not be good candidates for using the agent owing to its physical effects on the gut.[FDA Label, F4555, F4567, L
|
A vitamin D that can be regarded as a reduction product of vitamin D2.
|
Moderate
| 1
|
[
[
[
1037,
24,
1098
]
],
[
[
1037,
63,
386
],
[
386,
25,
1098
]
],
[
[
1037,
24,
1041
],
[
1041,
25,
1098
]
],
[
[
1037,
24,
1196
],
[
1196,
64,
1098
]
],
[
[
1037,
63,
1331
],
[
1331,
36,
1098
]
],
[
[
1037,
63,
386
],
[
386,
40,
1113
],
[
1113,
1,
1098
]
],
[
[
1037,
24,
1041
],
[
1041,
40,
1113
],
[
1113,
1,
1098
]
],
[
[
1037,
24,
1196
],
[
1196,
64,
386
],
[
386,
25,
1098
]
],
[
[
1037,
21,
28762
],
[
28762,
60,
1113
],
[
1113,
1,
1098
]
],
[
[
1037,
63,
386
],
[
386,
40,
11418
],
[
11418,
40,
1098
]
]
] |
[
[
[
"Colestipol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dihydrotachysterol"
]
],
[
[
"Colestipol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dihydrotachysterol"
]
],
[
[
"Colestipol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paricalcitol"
],
[
"Paricalcitol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dihydrotachysterol"
]
],
[
[
"Colestipol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxercalciferol"
],
[
"Doxercalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dihydrotachysterol"
]
],
[
[
"Colestipol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ergocalciferol"
],
[
"Ergocalciferol",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Dihydrotachysterol"
]
],
[
[
"Colestipol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} (Compound) resembles {v} (Compound)",
"Calcitriol"
],
[
"Calcitriol",
"{u} (Compound) resembles {v} (Compound)",
"Dihydrotachysterol"
]
],
[
[
"Colestipol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paricalcitol"
],
[
"Paricalcitol",
"{u} (Compound) resembles {v} (Compound)",
"Calcitriol"
],
[
"Calcitriol",
"{u} (Compound) resembles {v} (Compound)",
"Dihydrotachysterol"
]
],
[
[
"Colestipol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxercalciferol"
],
[
"Doxercalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dihydrotachysterol"
]
],
[
[
"Colestipol",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Calcitriol"
],
[
"Calcitriol",
"{u} (Compound) resembles {v} (Compound)",
"Dihydrotachysterol"
]
],
[
[
"Colestipol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} (Compound) resembles {v} (Compound)",
"Alfacalcidol"
],
[
"Alfacalcidol",
"{u} (Compound) resembles {v} (Compound)",
"Dihydrotachysterol"
]
]
] |
Colestipol may cause a moderate interaction that could exacerbate diseases when taken with Cholecalciferol and Cholecalciferol may lead to a major life threatening interaction when taken with Dihydrotachysterol
Colestipol may cause a moderate interaction that could exacerbate diseases when taken with Paricalcitol and Paricalcitol may lead to a major life threatening interaction when taken with Dihydrotachysterol
Colestipol may cause a moderate interaction that could exacerbate diseases when taken with Doxercalciferol and Doxercalciferol may lead to a major life threatening interaction when taken with Dihydrotachysterol
Colestipol may cause a moderate interaction that could exacerbate diseases when taken with Ergocalciferol and Ergocalciferol (Compound) resembles Dihydrotachysterol (Compound) and Ergocalciferol may lead to a major life threatening interaction when taken with Dihydrotachysterol
Colestipol may cause a moderate interaction that could exacerbate diseases when taken with Cholecalciferol and Cholecalciferol (Compound) resembles Calcitriol (Compound) and Calcitriol (Compound) resembles Dihydrotachysterol (Compound)
Colestipol may cause a moderate interaction that could exacerbate diseases when taken with Paricalcitol and Paricalcitol (Compound) resembles Calcitriol (Compound) and Calcitriol (Compound) resembles Dihydrotachysterol (Compound)
Colestipol may cause a moderate interaction that could exacerbate diseases when taken with Doxercalciferol and Doxercalciferol may lead to a major life threatening interaction when taken with Cholecalciferol and Cholecalciferol may lead to a major life threatening interaction when taken with Dihydrotachysterol
Colestipol (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Calcitriol (Compound) and Calcitriol (Compound) resembles Dihydrotachysterol (Compound)
Colestipol may cause a moderate interaction that could exacerbate diseases when taken with Cholecalciferol and Cholecalciferol (Compound) resembles Alfacalcidol (Compound) and Alfacalcidol (Compound) resembles Dihydrotachysterol (Compound)
|
DB00549
|
DB00909
| 522
| 306
|
[
"DDInter1955",
"DDInter1971"
] |
Zafirlukast
|
Zonisamide
|
Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages.
|
Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate.[L42530,L42535] Zonisamide represents an alternative for patients that remain refractory to established antiepileptic drugs. In 1989, it was approved for commercial use in Japan. The US and Europe approved it in 2000 and 2005, respectively.[A1379,A1383]
|
Moderate
| 1
|
[
[
[
522,
24,
306
]
],
[
[
522,
6,
8374
],
[
8374,
45,
306
]
],
[
[
522,
21,
28698
],
[
28698,
60,
306
]
],
[
[
522,
24,
159
],
[
159,
63,
306
]
],
[
[
522,
24,
723
],
[
723,
24,
306
]
],
[
[
522,
23,
222
],
[
222,
63,
306
]
],
[
[
522,
63,
597
],
[
597,
24,
306
]
],
[
[
522,
6,
8374
],
[
8374,
45,
609
],
[
609,
63,
306
]
],
[
[
522,
6,
10215
],
[
10215,
48,
11624
],
[
11624,
44,
306
]
],
[
[
522,
21,
28698
],
[
28698,
60,
609
],
[
609,
63,
306
]
]
] |
[
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zonisamide"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Zonisamide"
]
],
[
[
"Zafirlukast",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Zonisamide"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zonisamide"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zonisamide"
]
],
[
[
"Zafirlukast",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zonisamide"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zonisamide"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zonisamide"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is associated with {v} (Disease)",
"epilepsy syndrome"
],
[
"epilepsy syndrome",
"{u} (Disease) is treated by {v} (Compound)",
"Zonisamide"
]
],
[
[
"Zafirlukast",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zonisamide"
]
]
] |
Zafirlukast (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zonisamide (Compound)
Zafirlukast (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Zonisamide (Compound)
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Zonisamide
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Zonisamide
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Zonisamide
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Zonisamide
Zafirlukast (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clarithromycin (Compound) and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Zonisamide
Zafirlukast (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is associated with epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Zonisamide (Compound)
Zafirlukast (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Clarithromycin (Compound) and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Zonisamide
|
DB04899
|
DB08907
| 1,549
| 1,344
|
[
"DDInter1282",
"DDInter280"
] |
Nesiritide
|
Canagliflozin
|
Nesiritide is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing). Nesiritide is a 32 amino acid recombinant human B-type natriuretic peptide.
|
Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients .
|
Moderate
| 1
|
[
[
[
1549,
24,
1344
]
],
[
[
1549,
24,
549
],
[
549,
1,
1344
]
],
[
[
1549,
63,
714
],
[
714,
24,
1344
]
],
[
[
1549,
24,
1455
],
[
1455,
63,
1344
]
],
[
[
1549,
24,
549
],
[
549,
6,
16207
],
[
16207,
45,
1344
]
],
[
[
1549,
63,
714
],
[
714,
24,
549
],
[
549,
1,
1344
]
],
[
[
1549,
24,
1455
],
[
1455,
63,
549
],
[
549,
1,
1344
]
],
[
[
1549,
63,
1053
],
[
1053,
21,
29164
],
[
29164,
60,
1344
]
],
[
[
1549,
63,
714
],
[
714,
63,
1445
],
[
1445,
24,
1344
]
],
[
[
1549,
24,
1455
],
[
1455,
63,
1523
],
[
1523,
24,
1344
]
]
] |
[
[
[
"Nesiritide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Nesiritide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Nesiritide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Nesiritide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
],
[
"Nitrous acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Nesiritide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) binds {v} (Gene)",
"SLC5A1"
],
[
"SLC5A1",
"{u} (Gene) is bound by {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Nesiritide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Nesiritide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
],
[
"Nitrous acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Nesiritide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} (Compound) causes {v} (Side Effect)",
"Photosensitivity"
],
[
"Photosensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Nesiritide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Nesiritide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
],
[
"Nitrous acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
]
] |
Nesiritide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Nesiritide may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Nesiritide may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid and Nitrous acid may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Nesiritide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) binds SLC5A1 (Gene) and SLC5A1 (Gene) is bound by Canagliflozin (Compound)
Nesiritide may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Nesiritide may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid and Nitrous acid may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Nesiritide may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine (Compound) causes Photosensitivity (Side Effect) and Photosensitivity (Side Effect) is caused by Canagliflozin (Compound)
Nesiritide may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Nesiritide may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid and Nitrous acid may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
|
DB00443
|
DB00615
| 251
| 690
|
[
"DDInter195",
"DDInter1589"
] |
Betamethasone
|
Rifabutin
|
Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity.
|
A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.
|
Moderate
| 1
|
[
[
[
251,
24,
690
]
],
[
[
251,
24,
463
],
[
463,
1,
690
]
],
[
[
251,
6,
8374
],
[
8374,
45,
690
]
],
[
[
251,
7,
3727
],
[
3727,
46,
690
]
],
[
[
251,
6,
7720
],
[
7720,
46,
690
]
],
[
[
251,
21,
28996
],
[
28996,
60,
690
]
],
[
[
251,
63,
1101
],
[
1101,
23,
690
]
],
[
[
251,
24,
214
],
[
214,
63,
690
]
],
[
[
251,
63,
590
],
[
590,
24,
690
]
],
[
[
251,
1,
175
],
[
175,
63,
690
]
]
] |
[
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} (Compound) resembles {v} (Compound)",
"Rifabutin"
]
],
[
[
"Betamethasone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Rifabutin"
]
],
[
[
"Betamethasone",
"{u} (Compound) upregulates {v} (Gene)",
"MAL"
],
[
"MAL",
"{u} (Gene) is upregulated by {v} (Compound)",
"Rifabutin"
]
],
[
[
"Betamethasone",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Rifabutin"
]
],
[
[
"Betamethasone",
"{u} (Compound) causes {v} (Side Effect)",
"Musculoskeletal discomfort"
],
[
"Musculoskeletal discomfort",
"{u} (Side Effect) is caused by {v} (Compound)",
"Rifabutin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rifabutin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
]
]
] |
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin (Compound) resembles Rifabutin (Compound)
Betamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifabutin (Compound)
Betamethasone (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Rifabutin (Compound)
Betamethasone (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Rifabutin (Compound)
Betamethasone (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Rifabutin (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Rifabutin
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin
Betamethasone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin
|
DB01381
|
DB08899
| 958
| 129
|
[
"DDInter819",
"DDInter649"
] |
Ginkgo biloba
|
Enzalutamide
|
_Ginkgo biloba_ extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized extract of _Ginkgo biloba_ (EGb) 761 (EGb761), which was developed by a German pharmaceutical company in 1964. EGb761 contains 6% terpene lactones and 24% flavonoid glycosides. Flavonoids include quercetin, rutin, kaempferol, and isorhamnetin. Lactones include ginkgolide A, ginkgolide B, ginkgolide C, bilobalide, and
|
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.
|
Moderate
| 1
|
[
[
[
958,
24,
129
]
],
[
[
958,
63,
608
],
[
608,
23,
129
]
],
[
[
958,
63,
1010
],
[
1010,
24,
129
]
],
[
[
958,
24,
498
],
[
498,
63,
129
]
],
[
[
958,
24,
792
],
[
792,
25,
129
]
],
[
[
958,
24,
1670
],
[
1670,
64,
129
]
],
[
[
958,
63,
593
],
[
593,
25,
129
]
],
[
[
958,
63,
608
],
[
608,
6,
8374
],
[
8374,
45,
129
]
],
[
[
958,
63,
1010
],
[
1010,
24,
918
],
[
918,
1,
129
]
],
[
[
958,
63,
1264
],
[
1264,
63,
918
],
[
918,
1,
129
]
]
] |
[
[
[
"Ginkgo biloba",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Ginkgo biloba",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enzalutamide"
]
],
[
[
"Ginkgo biloba",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Ginkgo biloba",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Ginkgo biloba",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Ginkgo biloba",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Ginkgo biloba",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Ginkgo biloba",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Ginkgo biloba",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} (Compound) resembles {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Ginkgo biloba",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} (Compound) resembles {v} (Compound)",
"Enzalutamide"
]
]
] |
Ginkgo biloba may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Ginkgo biloba may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Ginkgo biloba may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban and Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Ginkgo biloba may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may lead to a major life threatening interaction when taken with Enzalutamide
Ginkgo biloba may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may lead to a major life threatening interaction when taken with Enzalutamide
Ginkgo biloba may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Enzalutamide
Ginkgo biloba may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Ginkgo biloba may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Ginkgo biloba may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
|
DB00188
|
DB15091
| 168
| 676
|
[
"DDInter222",
"DDInter1901"
] |
Bortezomib
|
Upadacitinib
|
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic
|
Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration.
|
Major
| 2
|
[
[
[
168,
25,
676
]
],
[
[
168,
63,
1461
],
[
1461,
23,
676
]
],
[
[
168,
24,
1430
],
[
1430,
24,
676
]
],
[
[
168,
23,
1249
],
[
1249,
24,
676
]
],
[
[
168,
23,
1654
],
[
1654,
63,
676
]
],
[
[
168,
25,
690
],
[
690,
24,
676
]
],
[
[
168,
63,
1184
],
[
1184,
25,
676
]
],
[
[
168,
24,
859
],
[
859,
25,
676
]
],
[
[
168,
25,
697
],
[
697,
25,
676
]
],
[
[
168,
64,
1066
],
[
1066,
25,
676
]
]
] |
[
[
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Upadacitinib"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nafcillin"
],
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somapacitan"
],
[
"Somapacitan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rifabutin"
],
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
],
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
]
] |
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Nafcillin and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Bortezomib may lead to a major life threatening interaction when taken with Rifabutin and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole and Posaconazole may lead to a major life threatening interaction when taken with Upadacitinib
Bortezomib may lead to a major life threatening interaction when taken with Phenobarbital and Phenobarbital may lead to a major life threatening interaction when taken with Upadacitinib
Bortezomib may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Upadacitinib
|
DB00773
|
DB09118
| 896
| 1,580
|
[
"DDInter702",
"DDInter1711"
] |
Etoposide
|
Stiripentol
|
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
|
Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes. However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs, hence boosting their therapeutic efficacy. Stiripentol may also exhibit direct anticonvulsant properties, although the exact mechanism of action is fully understood. Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit.
|
Moderate
| 1
|
[
[
[
896,
24,
1580
]
],
[
[
896,
24,
283
],
[
283,
63,
1580
]
],
[
[
896,
63,
168
],
[
168,
24,
1580
]
],
[
[
896,
24,
1532
],
[
1532,
24,
1580
]
],
[
[
896,
25,
976
],
[
976,
24,
1580
]
],
[
[
896,
25,
676
],
[
676,
63,
1580
]
],
[
[
896,
25,
1292
],
[
1292,
25,
1580
]
],
[
[
896,
24,
1362
],
[
1362,
25,
1580
]
],
[
[
896,
24,
927
],
[
927,
64,
1580
]
],
[
[
896,
24,
283
],
[
283,
23,
466
],
[
466,
62,
1580
]
]
] |
[
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Etoposide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Etoposide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Etoposide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stiripentol"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stiripentol"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stiripentol"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Stiripentol"
]
]
] |
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Etoposide may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Etoposide may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Etoposide may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Stiripentol
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may lead to a major life threatening interaction when taken with Stiripentol
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may lead to a major life threatening interaction when taken with Stiripentol
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Stiripentol
|
DB00095
|
DB08904
| 66
| 375
|
[
"DDInter623",
"DDInter342"
] |
Efalizumab
|
Certolizumab pegol
|
Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).
|
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019.
|
Moderate
| 1
|
[
[
[
66,
24,
375
]
],
[
[
66,
23,
1461
],
[
1461,
23,
375
]
],
[
[
66,
23,
1193
],
[
1193,
62,
375
]
],
[
[
66,
24,
1367
],
[
1367,
63,
375
]
],
[
[
66,
24,
1430
],
[
1430,
24,
375
]
],
[
[
66,
63,
58
],
[
58,
24,
375
]
],
[
[
66,
24,
881
],
[
881,
25,
375
]
],
[
[
66,
25,
1066
],
[
1066,
25,
375
]
],
[
[
66,
24,
398
],
[
398,
64,
375
]
],
[
[
66,
63,
669
],
[
669,
25,
375
]
]
] |
[
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
],
[
"Hepatitis B Vaccine (Recombinant)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abatacept"
],
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Efalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tildrakizumab"
],
[
"Tildrakizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denileukin diftitox"
],
[
"Denileukin diftitox",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
]
] |
Efalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant) and Hepatitis B Vaccine (Recombinant) may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Abatacept and Abatacept may lead to a major life threatening interaction when taken with Certolizumab pegol
Efalizumab may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Tildrakizumab and Tildrakizumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Denileukin diftitox and Denileukin diftitox may lead to a major life threatening interaction when taken with Certolizumab pegol
|
DB00761
|
DB00939
| 1,621
| 1,338
|
[
"DDInter1497",
"DDInter1135"
] |
Potassium chloride
|
Meclofenamic acid
|
A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium per dosage unit, except for controlled-release dosage forms and those products formulated for preparation of solution prior to ingestion.
|
A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.
|
Moderate
| 1
|
[
[
[
1621,
24,
1338
]
],
[
[
1621,
21,
28900
],
[
28900,
60,
1338
]
],
[
[
1621,
63,
1274
],
[
1274,
24,
1338
]
],
[
[
1621,
24,
848
],
[
848,
63,
1338
]
],
[
[
1621,
63,
1512
],
[
1512,
35,
1338
]
],
[
[
1621,
21,
28900
],
[
28900,
60,
345
],
[
345,
1,
1338
]
],
[
[
1621,
63,
1274
],
[
1274,
40,
345
],
[
345,
1,
1338
]
],
[
[
1621,
24,
848
],
[
848,
64,
1479
],
[
1479,
63,
1338
]
],
[
[
1621,
40,
803
],
[
803,
21,
29196
],
[
29196,
60,
1338
]
],
[
[
1621,
21,
28714
],
[
28714,
60,
1127
],
[
1127,
23,
1338
]
]
] |
[
[
[
"Potassium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Potassium chloride",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Meclofenamic acid"
]
],
[
[
"Potassium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Potassium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Potassium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Potassium chloride",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Salsalate"
],
[
"Salsalate",
"{u} (Compound) resembles {v} (Compound)",
"Meclofenamic acid"
]
],
[
[
"Potassium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} (Compound) resembles {v} (Compound)",
"Salsalate"
],
[
"Salsalate",
"{u} (Compound) resembles {v} (Compound)",
"Meclofenamic acid"
]
],
[
[
"Potassium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Potassium chloride",
"{u} (Compound) resembles {v} (Compound)",
"Calcium chloride"
],
[
"Calcium chloride",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Meclofenamic acid"
]
],
[
[
"Potassium chloride",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nizatidine"
],
[
"Nizatidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Meclofenamic acid"
]
]
] |
Potassium chloride (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Meclofenamic acid (Compound)
Potassium chloride may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Potassium chloride may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Potassium chloride may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac (Compound) resembles Meclofenamic acid (Compound) and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Potassium chloride (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Salsalate (Compound) and Salsalate (Compound) resembles Meclofenamic acid (Compound)
Potassium chloride may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen (Compound) resembles Salsalate (Compound) and Salsalate (Compound) resembles Meclofenamic acid (Compound)
Potassium chloride may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Potassium chloride (Compound) resembles Calcium chloride (Compound) and Calcium chloride (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Meclofenamic acid (Compound)
Potassium chloride (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Nizatidine (Compound) and Nizatidine may cause a minor interaction that can limit clinical effects when taken with Meclofenamic acid
|
DB09074
|
DB12010
| 1,362
| 214
|
[
"DDInter1327",
"DDInter785"
] |
Olaparib
|
Fostamatinib
|
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016.
|
Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018]
|
Moderate
| 1
|
[
[
[
1362,
24,
214
]
],
[
[
1362,
64,
976
],
[
976,
24,
214
]
],
[
[
1362,
24,
861
],
[
861,
63,
214
]
],
[
[
1362,
63,
866
],
[
866,
24,
214
]
],
[
[
1362,
24,
738
],
[
738,
24,
214
]
],
[
[
1362,
25,
1155
],
[
1155,
24,
214
]
],
[
[
1362,
25,
676
],
[
676,
63,
214
]
],
[
[
1362,
64,
609
],
[
609,
25,
214
]
],
[
[
1362,
24,
230
],
[
230,
25,
214
]
],
[
[
1362,
63,
990
],
[
990,
25,
214
]
]
] |
[
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
],
[
"Ripretinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
],
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
],
[
"Tucatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
],
[
"Relugolix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
]
] |
Olaparib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib and Ripretinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib and Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Olaparib may lead to a major life threatening interaction when taken with Tucatinib and Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Olaparib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Olaparib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Fostamatinib
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Relugolix and Relugolix may lead to a major life threatening interaction when taken with Fostamatinib
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Fostamatinib
|
DB00350
|
DB00831
| 1,214
| 1,178
|
[
"DDInter1226",
"DDInter1866"
] |
Minoxidil
|
Trifluoperazine
|
A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.
|
A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.
|
Moderate
| 1
|
[
[
[
1214,
24,
1178
]
],
[
[
1214,
24,
695
],
[
695,
40,
1178
]
],
[
[
1214,
24,
9
],
[
9,
1,
1178
]
],
[
[
1214,
24,
1376
],
[
1376,
63,
1178
]
],
[
[
1214,
24,
999
],
[
999,
24,
1178
]
],
[
[
1214,
63,
1648
],
[
1648,
24,
1178
]
],
[
[
1214,
24,
593
],
[
593,
64,
1178
]
],
[
[
1214,
63,
475
],
[
475,
25,
1178
]
],
[
[
1214,
24,
104
],
[
104,
74,
1178
]
],
[
[
1214,
24,
695
],
[
695,
40,
11372
],
[
11372,
1,
1178
]
]
] |
[
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
],
[
"Methotrimeprazine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound)",
"Zuclopenthixol"
],
[
"Zuclopenthixol",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
]
]
] |
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Trifluoperazine (Compound)
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine and Methotrimeprazine (Compound) resembles Trifluoperazine (Compound)
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Trifluoperazine
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Trifluoperazine
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Trifluoperazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Zuclopenthixol (Compound) and Zuclopenthixol (Compound) resembles Trifluoperazine (Compound)
|
DB00347
|
DB01069
| 917
| 401
|
[
"DDInter1871",
"DDInter1533"
] |
Trimethadione
|
Promethazine
|
An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)
|
Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000]
|
Moderate
| 1
|
[
[
[
917,
24,
401
]
],
[
[
917,
24,
1264
],
[
1264,
63,
401
]
],
[
[
917,
6,
6017
],
[
6017,
45,
401
]
],
[
[
917,
21,
28709
],
[
28709,
60,
401
]
],
[
[
917,
63,
701
],
[
701,
24,
401
]
],
[
[
917,
24,
13
],
[
13,
24,
401
]
],
[
[
917,
24,
1487
],
[
1487,
64,
401
]
],
[
[
917,
24,
1264
],
[
1264,
63,
146
],
[
146,
24,
401
]
],
[
[
917,
6,
6017
],
[
6017,
45,
1264
],
[
1264,
63,
401
]
],
[
[
917,
21,
28709
],
[
28709,
60,
1264
],
[
1264,
63,
401
]
]
] |
[
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Trimethadione",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Promethazine"
]
],
[
[
"Trimethadione",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Promethazine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
],
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Trimethadione",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Trimethadione",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
]
] |
Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Trimethadione (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Promethazine (Compound)
Trimethadione (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Promethazine (Compound)
Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Promethazine
Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Trimethadione (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Doxepin (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Trimethadione (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Doxepin (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
|
DB09075
|
DB11689
| 498
| 321
|
[
"DDInter621",
"DDInter1659"
] |
Edoxaban
|
Selumetinib
|
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and
|
Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating earlier developed MEK inhibitors were underwhelming. However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading to its continued investigation for the treatment of various types of tumours in Phase II trials. Currently, the novel MEK 1 / 2 inhibitor, selumetinib, is approved solely for the treatment of Neurofibromatosis type 1 (NF-1) in a limited age group. NF-1 is considered rare, with an estimated incidence of 1/3000 individuals. It is a genetic, autosomal dominant condition resulting from mutations of the NF1 gene, which can lead to various complications, including the development of multiple tumours in the nervous system.[A193533,A193608] Some patients with this disorder develop plexiform neurofibromas (PN); however, this is considered relatively uncommon compared to other variants of NF-1. Luckily, the use of selumetinib in patients with NF-1 have shown efficacy in shrinking associated tumours and is linked to other positive clinical outcomes. Selumetinib was approved by the FDA on April 10, 2020. It was later approved by Health Canada on August 23, 2022.
|
Moderate
| 1
|
[
[
[
498,
24,
321
]
],
[
[
498,
24,
298
],
[
298,
24,
321
]
],
[
[
498,
64,
291
],
[
291,
24,
321
]
],
[
[
498,
25,
1421
],
[
1421,
63,
321
]
],
[
[
498,
25,
235
],
[
235,
24,
321
]
],
[
[
498,
24,
1476
],
[
1476,
63,
321
]
],
[
[
498,
24,
913
],
[
913,
64,
321
]
],
[
[
498,
63,
129
],
[
129,
25,
321
]
],
[
[
498,
64,
609
],
[
609,
25,
321
]
],
[
[
498,
25,
283
],
[
283,
64,
321
]
]
] |
[
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protein C"
],
[
"Protein C",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Argatroban"
],
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Selumetinib"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Selumetinib"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Selumetinib"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Selumetinib"
]
]
] |
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Protein C and Protein C may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Edoxaban may lead to a major life threatening interaction when taken with Argatroban and Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Edoxaban may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Edoxaban may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Selumetinib
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Selumetinib
Edoxaban may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Selumetinib
Edoxaban may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Selumetinib
|
DB00916
|
DB06589
| 112
| 1,250
|
[
"DDInter1202",
"DDInter1400"
] |
Metronidazole
|
Pazopanib
|
Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.
|
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
|
Minor
| 0
|
[
[
[
112,
23,
1250
]
],
[
[
112,
6,
3486
],
[
3486,
45,
1250
]
],
[
[
112,
21,
28868
],
[
28868,
60,
1250
]
],
[
[
112,
23,
1247
],
[
1247,
23,
1250
]
],
[
[
112,
63,
479
],
[
479,
23,
1250
]
],
[
[
112,
62,
1630
],
[
1630,
24,
1250
]
],
[
[
112,
23,
1151
],
[
1151,
24,
1250
]
],
[
[
112,
24,
651
],
[
651,
24,
1250
]
],
[
[
112,
63,
288
],
[
288,
24,
1250
]
],
[
[
112,
23,
913
],
[
913,
63,
1250
]
]
] |
[
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pazopanib"
]
],
[
[
"Metronidazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Pazopanib"
]
],
[
[
"Metronidazole",
"{u} (Compound) causes {v} (Side Effect)",
"Stomatitis"
],
[
"Stomatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pazopanib"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pazopanib"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pazopanib"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Perphenazine"
],
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Butalbital"
],
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
]
] |
Metronidazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Pazopanib (Compound)
Metronidazole (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effect) is caused by Pazopanib (Compound)
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Pazopanib
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Pazopanib
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Perphenazine and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Butalbital and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
|
DB01168
|
DB01452
| 1,053
| 993
|
[
"DDInter1526",
"DDInter532"
] |
Procarbazine
|
Diamorphine
|
An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
|
Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is controlled under Schedules I and IV of the Single Convention on Narcotic Drugs. As heroin, it is illegal to manufacture, possess, or sell in the United States and the UK. However, under the name diamorphine, heroin is a legal prescription drug in the United Kingdom.
|
Major
| 2
|
[
[
[
1053,
25,
993
]
],
[
[
1053,
64,
421
],
[
421,
40,
993
]
],
[
[
1053,
64,
475
],
[
475,
25,
993
]
],
[
[
1053,
25,
22
],
[
22,
23,
993
]
],
[
[
1053,
24,
1637
],
[
1637,
63,
993
]
],
[
[
1053,
63,
13
],
[
13,
24,
993
]
],
[
[
1053,
64,
770
],
[
770,
24,
993
]
],
[
[
1053,
25,
1609
],
[
1609,
63,
993
]
],
[
[
1053,
24,
1311
],
[
1311,
24,
993
]
],
[
[
1053,
64,
421
],
[
421,
1,
1044
],
[
1044,
40,
993
]
]
] |
[
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diamorphine"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydromorphone"
],
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Diamorphine"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diamorphine"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Diamorphine"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
],
[
"Amyl Nitrite",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diamorphine"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diamorphine"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diamorphine"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diamorphine"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diamorphine"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydromorphone"
],
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Codeine"
],
[
"Codeine",
"{u} (Compound) resembles {v} (Compound)",
"Diamorphine"
]
]
] |
Procarbazine may lead to a major life threatening interaction when taken with Hydromorphone and Hydromorphone (Compound) resembles Diamorphine (Compound)
Procarbazine may lead to a major life threatening interaction when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Diamorphine
Procarbazine may lead to a major life threatening interaction when taken with Ephedrine and Ephedrine may cause a minor interaction that can limit clinical effects when taken with Diamorphine
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite and Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Diamorphine
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Diamorphine
Procarbazine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Diamorphine
Procarbazine may lead to a major life threatening interaction when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Diamorphine
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Diamorphine
Procarbazine may lead to a major life threatening interaction when taken with Hydromorphone and Hydromorphone (Compound) resembles Codeine (Compound) and Codeine (Compound) resembles Diamorphine (Compound)
|
DB00909
|
DB11901
| 306
| 913
|
[
"DDInter1971",
"DDInter107"
] |
Zonisamide
|
Apalutamide
|
Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate.[L42530,L42535] Zonisamide represents an alternative for patients that remain refractory to established antiepileptic drugs. In 1989, it was approved for commercial use in Japan. The US and Europe approved it in 2000 and 2005, respectively.[A1379,A1383]
|
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors . In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or . Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines . Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which is the second-most common cause of cancer-related deaths in American males . Castration-resistant prostate cancer is often incurable, which poses significant clinical challenges for patients. Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis . Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death . In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment . In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo . Apalutamide displayed good tolerability and safety profile in clinical studies. Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant). It is available as oral tablets. Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer .
|
Moderate
| 1
|
[
[
[
306,
24,
913
]
],
[
[
306,
63,
600
],
[
600,
24,
913
]
],
[
[
306,
24,
609
],
[
609,
24,
913
]
],
[
[
306,
24,
1619
],
[
1619,
63,
913
]
],
[
[
306,
25,
401
],
[
401,
24,
913
]
],
[
[
306,
24,
283
],
[
283,
64,
913
]
],
[
[
306,
24,
1213
],
[
1213,
25,
913
]
],
[
[
306,
63,
1419
],
[
1419,
25,
913
]
],
[
[
306,
63,
600
],
[
600,
25,
312
],
[
312,
23,
913
]
],
[
[
306,
24,
609
],
[
609,
64,
312
],
[
312,
23,
913
]
]
] |
[
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Zonisamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eplerenone"
],
[
"Eplerenone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
],
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eplerenone"
],
[
"Eplerenone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
]
] |
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Zonisamide may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Apalutamide
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Apalutamide
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Apalutamide
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Eplerenone and Eplerenone may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Eplerenone and Eplerenone may cause a minor interaction that can limit clinical effects when taken with Apalutamide
|
DB00023
|
DB00624
| 305
| 1,561
|
[
"DDInter127",
"DDInter1775"
] |
Asparaginase Escherichia coli
|
Testosterone
|
Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997]. L-asparaginase of _E. coli_ is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections. Therapeutic L-asparaginase from _E. coli_ works by depleting the levels
|
Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.[A187114,L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone was isolated from samples and also synthesized in 1935.
|
Moderate
| 1
|
[
[
[
305,
24,
1561
]
],
[
[
305,
24,
155
],
[
155,
1,
1561
]
],
[
[
305,
24,
1026
],
[
1026,
40,
1561
]
],
[
[
305,
24,
891
],
[
891,
63,
1561
]
],
[
[
305,
24,
322
],
[
322,
24,
1561
]
],
[
[
305,
25,
1510
],
[
1510,
64,
1561
]
],
[
[
305,
24,
126
],
[
126,
64,
1561
]
],
[
[
305,
24,
155
],
[
155,
40,
443
],
[
443,
1,
1561
]
],
[
[
305,
24,
891
],
[
891,
63,
443
],
[
443,
1,
1561
]
],
[
[
305,
24,
322
],
[
322,
24,
1026
],
[
1026,
40,
1561
]
]
] |
[
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxymesterone"
],
[
"Fluoxymesterone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
],
[
"Oxandrolone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Testosterone"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Testosterone"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxymesterone"
],
[
"Fluoxymesterone",
"{u} (Compound) resembles {v} (Compound)",
"Spironolactone"
],
[
"Spironolactone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Spironolactone"
],
[
"Spironolactone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
],
[
"Oxandrolone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
]
]
] |
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Fluoxymesterone and Fluoxymesterone (Compound) resembles Testosterone (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone and Oxandrolone (Compound) resembles Testosterone (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Testosterone
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Testosterone
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Testosterone
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Testosterone
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Fluoxymesterone and Fluoxymesterone (Compound) resembles Spironolactone (Compound) and Spironolactone (Compound) resembles Testosterone (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Spironolactone and Spironolactone (Compound) resembles Testosterone (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone and Oxandrolone (Compound) resembles Testosterone (Compound)
|
DB00039
|
DB00570
| 1,253
| 147
|
[
"DDInter1380",
"DDInter1936"
] |
Palifermin
|
Vinblastine
|
Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.
|
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
|
Moderate
| 1
|
[
[
[
1253,
24,
147
]
],
[
[
1253,
24,
134
],
[
134,
24,
147
]
],
[
[
1253,
24,
970
],
[
970,
23,
147
]
],
[
[
1253,
24,
37
],
[
37,
62,
147
]
],
[
[
1253,
24,
995
],
[
995,
63,
147
]
],
[
[
1253,
63,
268
],
[
268,
24,
147
]
],
[
[
1253,
24,
1064
],
[
1064,
25,
147
]
],
[
[
1253,
24,
770
],
[
770,
64,
147
]
],
[
[
1253,
24,
134
],
[
134,
40,
11503
],
[
11503,
40,
147
]
],
[
[
1253,
24,
970
],
[
970,
63,
134
],
[
134,
24,
147
]
]
] |
[
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
],
[
"Fluorouracil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vinblastine"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
],
[
"Lomustine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vinblastine"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyurea"
],
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
],
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinblastine"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinblastine"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} (Compound) resembles {v} (Compound)",
"Vindesine"
],
[
"Vindesine",
"{u} (Compound) resembles {v} (Compound)",
"Vinblastine"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
],
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
]
] |
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil and Fluorouracil may cause a minor interaction that can limit clinical effects when taken with Vinblastine
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a minor interaction that can limit clinical effects when taken with Vinblastine
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea and Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Vinblastine
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Vinblastine
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine (Compound) resembles Vindesine (Compound) and Vindesine (Compound) resembles Vinblastine (Compound)
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil and Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
|
DB08882
|
DB12147
| 1,281
| 241
|
[
"DDInter1070",
"DDInter661"
] |
Linagliptin
|
Erdafitinib
|
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
|
In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. [L5956, L5959] At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy [L5956, L5959]. Erdafitinib is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the development of more personalized and precise medicines tailoring to a patient's specific genetic mutation.[L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic tool kit to treat such a prevalent medical condition.
|
Moderate
| 1
|
[
[
[
1281,
24,
241
]
],
[
[
1281,
24,
982
],
[
982,
63,
241
]
],
[
[
1281,
63,
850
],
[
850,
24,
241
]
],
[
[
1281,
63,
1220
],
[
1220,
25,
241
]
],
[
[
1281,
24,
1017
],
[
1017,
25,
241
]
],
[
[
1281,
24,
982
],
[
982,
63,
1456
],
[
1456,
24,
241
]
],
[
[
1281,
63,
850
],
[
850,
63,
170
],
[
170,
24,
241
]
],
[
[
1281,
63,
629
],
[
629,
24,
170
],
[
170,
24,
241
]
],
[
[
1281,
24,
1017
],
[
1017,
64,
1456
],
[
1456,
24,
241
]
],
[
[
1281,
24,
1604
],
[
1604,
25,
982
],
[
982,
63,
241
]
]
] |
[
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
]
] |
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Erdafitinib
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Erdafitinib
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
|
DB00704
|
DB06210
| 267
| 72
|
[
"DDInter1263",
"DDInter631"
] |
Naltrexone
|
Eltrombopag
|
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
|
Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
|
Moderate
| 1
|
[
[
[
267,
24,
72
]
],
[
[
267,
6,
15705
],
[
15705,
45,
72
]
],
[
[
267,
24,
384
],
[
384,
63,
72
]
],
[
[
267,
63,
467
],
[
467,
24,
72
]
],
[
[
267,
24,
700
],
[
700,
24,
72
]
],
[
[
267,
63,
268
],
[
268,
25,
72
]
],
[
[
267,
25,
990
],
[
990,
64,
72
]
],
[
[
267,
25,
1070
],
[
1070,
25,
72
]
],
[
[
267,
24,
350
],
[
350,
64,
72
]
],
[
[
267,
6,
15705
],
[
15705,
45,
467
],
[
467,
24,
72
]
]
] |
[
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Naltrexone",
"{u} (Compound) binds {v} (Gene)",
"UGT1A1"
],
[
"UGT1A1",
"{u} (Gene) is bound by {v} (Compound)",
"Eltrombopag"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
],
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
],
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eltrombopag"
]
],
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eltrombopag"
]
],
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
],
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eltrombopag"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eltrombopag"
]
],
[
[
"Naltrexone",
"{u} (Compound) binds {v} (Gene)",
"UGT1A1"
],
[
"UGT1A1",
"{u} (Gene) is bound by {v} (Compound)",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
]
] |
Naltrexone (Compound) binds UGT1A1 (Gene) and UGT1A1 (Gene) is bound by Eltrombopag (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Eltrombopag
Naltrexone may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Eltrombopag
Naltrexone may lead to a major life threatening interaction when taken with Mipomersen and Mipomersen may lead to a major life threatening interaction when taken with Eltrombopag
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may lead to a major life threatening interaction when taken with Eltrombopag
Naltrexone (Compound) binds UGT1A1 (Gene) and UGT1A1 (Gene) is bound by Simvastatin (Compound) and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
|
DB00372
|
DB01114
| 999
| 272
|
[
"DDInter1793",
"DDInter362"
] |
Thiethylperazine
|
Chlorpheniramine
|
A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457)
|
A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine.
|
Moderate
| 1
|
[
[
[
999,
24,
272
]
],
[
[
999,
24,
358
],
[
358,
63,
272
]
],
[
[
999,
24,
128
],
[
128,
24,
272
]
],
[
[
999,
63,
1242
],
[
1242,
24,
272
]
],
[
[
999,
25,
730
],
[
730,
63,
272
]
],
[
[
999,
25,
684
],
[
684,
24,
272
]
],
[
[
999,
64,
534
],
[
534,
24,
272
]
],
[
[
999,
25,
675
],
[
675,
25,
272
]
],
[
[
999,
24,
1376
],
[
1376,
35,
272
]
],
[
[
999,
63,
1594
],
[
1594,
35,
272
]
]
] |
[
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
],
[
"Deutetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
]
] |
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Thiethylperazine may lead to a major life threatening interaction when taken with Deutetrabenazine and Deutetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Thiethylperazine may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Thiethylperazine may lead to a major life threatening interaction when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Thiethylperazine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Chlorpheniramine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Chlorpheniramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Chlorpheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
|
DB00939
|
DB00959
| 1,338
| 1,486
|
[
"DDInter1135",
"DDInter1191"
] |
Meclofenamic acid
|
Methylprednisolone
|
A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.
|
Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.
|
Moderate
| 1
|
[
[
[
1338,
24,
1486
]
],
[
[
1338,
63,
175
],
[
175,
40,
1486
]
],
[
[
1338,
63,
167
],
[
167,
1,
1486
]
],
[
[
1338,
24,
1220
],
[
1220,
1,
1486
]
],
[
[
1338,
24,
617
],
[
617,
40,
1486
]
],
[
[
1338,
21,
28997
],
[
28997,
60,
1486
]
],
[
[
1338,
63,
1018
],
[
1018,
23,
1486
]
],
[
[
1338,
24,
1479
],
[
1479,
24,
1486
]
],
[
[
1338,
63,
1560
],
[
1560,
24,
1486
]
],
[
[
1338,
64,
629
],
[
629,
24,
1486
]
]
] |
[
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Meclofenamic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Ill-defined disorder"
],
[
"Ill-defined disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Meclofenamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
]
] |
Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Methylprednisolone (Compound)
Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Methylprednisolone (Compound)
Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Methylprednisolone (Compound)
Meclofenamic acid (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Methylprednisolone (Compound)
Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone
Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Meclofenamic acid may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
|
DB00795
|
DB09420
| 50
| 1,074
|
[
"DDInter1725",
"DDInter953"
] |
Sulfasalazine
|
Iodide I-123
|
Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulf
|
Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect the decay by electron capture to tellurium-123. Iodine is commonly used in thyroid function diagnostic tests as this gland normally absorbs iodine through the diet for formation of the thyroid hormones triiodothyronine (T3) and its prohormone, thyroxine (T4). Radioactive I-123 in particular is effective for this use as its half-life of approximately 13.13 h (hours) is ideal for the 24-h (hour) iodine uptake test and it has a reduced radiation burden as compared to I-131.
|
Moderate
| 1
|
[
[
[
50,
24,
1074
]
],
[
[
50,
40,
161
],
[
161,
24,
1074
]
],
[
[
50,
64,
126
],
[
126,
24,
1074
]
],
[
[
50,
25,
777
],
[
777,
24,
1074
]
],
[
[
50,
63,
485
],
[
485,
24,
1074
]
],
[
[
50,
24,
1411
],
[
1411,
24,
1074
]
],
[
[
50,
24,
1399
],
[
1399,
63,
1074
]
],
[
[
50,
62,
682
],
[
682,
24,
1074
]
],
[
[
50,
40,
161
],
[
161,
25,
126
],
[
126,
24,
1074
]
],
[
[
50,
64,
126
],
[
126,
64,
161
],
[
161,
24,
1074
]
]
] |
[
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Sulfasalazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Sulfasalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Sulfasalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iopromide"
],
[
"Iopromide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Sulfasalazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Thiopental"
],
[
"Thiopental",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Sulfasalazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Sulfasalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
]
] |
Sulfasalazine (Compound) resembles Sulfadiazine (Compound) and Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Sulfasalazine may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Sulfasalazine may lead to a major life threatening interaction when taken with Iopromide and Iopromide may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Sulfasalazine may cause a minor interaction that can limit clinical effects when taken with Thiopental and Thiopental may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Sulfasalazine (Compound) resembles Sulfadiazine (Compound) and Sulfadiazine may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Sulfasalazine may lead to a major life threatening interaction when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Sulfadiazine and Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
|
DB06650
|
DB10316
| 1,500
| 334
|
[
"DDInter1324",
"DDInter1248"
] |
Ofatumumab
|
Mumps virus strain B level jeryl lynn live antigen
|
Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and can also be found in normal B-cells. Ofatumumab was first approved by the FDA in 2009. It is used in the treatment of recurrent, progressive, or recurrent chronic lymphocytic leukemia (CLL) or CLL in treatment-naive patients in whom fludarabine-based therapy is considered inappropriate. Ofatumumab is used as monotherapy or in combination with other medications, depending on the patient profile and previous treatment history. Although it has a similar molecular mechanism of action as [rituximab], another CD-
|
Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease.
|
Major
| 2
|
[
[
[
1500,
25,
334
]
],
[
[
1500,
64,
1057
],
[
1057,
25,
334
]
],
[
[
1500,
25,
908
],
[
908,
25,
334
]
],
[
[
1500,
63,
599
],
[
599,
25,
334
]
],
[
[
1500,
25,
1259
],
[
1259,
64,
334
]
],
[
[
1500,
24,
713
],
[
713,
25,
334
]
],
[
[
1500,
24,
270
],
[
270,
64,
334
]
],
[
[
1500,
64,
1057
],
[
1057,
25,
1042
],
[
1042,
24,
334
]
],
[
[
1500,
25,
908
],
[
908,
64,
1042
],
[
1042,
24,
334
]
],
[
[
1500,
63,
599
],
[
599,
24,
1042
],
[
1042,
24,
334
]
]
] |
[
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
]
] |
Ofatumumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Ofatumumab may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Ofatumumab may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Ofatumumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen
Ofatumumab may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen
|
DB00734
|
DB01218
| 1,664
| 1,493
|
[
"DDInter1605",
"DDInter852"
] |
Risperidone
|
Halofantrine
|
Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone). Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively. Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain. Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's
|
Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity.
|
Major
| 2
|
[
[
[
1664,
25,
1493
]
],
[
[
1664,
6,
12523
],
[
12523,
45,
1493
]
],
[
[
1664,
21,
28810
],
[
28810,
60,
1493
]
],
[
[
1664,
23,
112
],
[
112,
23,
1493
]
],
[
[
1664,
24,
770
],
[
770,
24,
1493
]
],
[
[
1664,
24,
657
],
[
657,
63,
1493
]
],
[
[
1664,
63,
355
],
[
355,
24,
1493
]
],
[
[
1664,
24,
1213
],
[
1213,
64,
1493
]
],
[
[
1664,
63,
79
],
[
79,
25,
1493
]
],
[
[
1664,
25,
982
],
[
982,
64,
1493
]
]
] |
[
[
[
"Risperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Risperidone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Halofantrine"
]
],
[
[
"Risperidone",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Halofantrine"
]
],
[
[
"Risperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Halofantrine"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halofantrine"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
],
[
"Castor oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halofantrine"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halofantrine"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Risperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
]
] |
Risperidone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Halofantrine (Compound)
Risperidone (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Halofantrine (Compound)
Risperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Halofantrine
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Halofantrine
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Halofantrine
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Halofantrine
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Halofantrine
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may lead to a major life threatening interaction when taken with Halofantrine
Risperidone may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Halofantrine
|
DB01166
|
DB01254
| 477
| 1,213
|
[
"DDInter379",
"DDInter484"
] |
Cilostazol
|
Dasatinib
|
Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
|
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186]
|
Major
| 2
|
[
[
[
477,
25,
1213
]
],
[
[
477,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
477,
7,
3422
],
[
3422,
46,
1213
]
],
[
[
477,
18,
4303
],
[
4303,
57,
1213
]
],
[
[
477,
21,
28882
],
[
28882,
60,
1213
]
],
[
[
477,
62,
1247
],
[
1247,
23,
1213
]
],
[
[
477,
63,
479
],
[
479,
23,
1213
]
],
[
[
477,
23,
539
],
[
539,
62,
1213
]
],
[
[
477,
24,
738
],
[
738,
63,
1213
]
],
[
[
477,
63,
1133
],
[
1133,
24,
1213
]
]
] |
[
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Cilostazol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Cilostazol",
"{u} (Compound) upregulates {v} (Gene)",
"SATB1"
],
[
"SATB1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Cilostazol",
"{u} (Compound) downregulates {v} (Gene)",
"CLTB"
],
[
"CLTB",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Cilostazol",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dasatinib"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dasatinib"
]
],
[
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dasatinib"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
]
] |
Cilostazol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Cilostazol (Compound) upregulates SATB1 (Gene) and SATB1 (Gene) is upregulated by Dasatinib (Compound)
Cilostazol (Compound) downregulates CLTB (Gene) and CLTB (Gene) is downregulated by Dasatinib (Compound)
Cilostazol (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Cilostazol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Cilostazol may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
|
DB01169
|
DB01177
| 57
| 77
|
[
"DDInter120",
"DDInter904"
] |
Arsenic trioxide
|
Idarubicin
|
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
|
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
|
Major
| 2
|
[
[
[
57,
25,
77
]
],
[
[
57,
6,
2067
],
[
2067,
46,
77
]
],
[
[
57,
6,
3517
],
[
3517,
57,
77
]
],
[
[
57,
64,
739
],
[
739,
23,
77
]
],
[
[
57,
62,
1247
],
[
1247,
23,
77
]
],
[
[
57,
25,
823
],
[
823,
63,
77
]
],
[
[
57,
63,
543
],
[
543,
24,
77
]
],
[
[
57,
64,
918
],
[
918,
24,
77
]
],
[
[
57,
24,
673
],
[
673,
63,
77
]
],
[
[
57,
64,
246
],
[
246,
25,
77
]
]
] |
[
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
]
],
[
[
"Arsenic trioxide",
"{u} (Compound) binds {v} (Gene)",
"IKBKB"
],
[
"IKBKB",
"{u} (Gene) is upregulated by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Arsenic trioxide",
"{u} (Compound) binds {v} (Gene)",
"TXNRD1"
],
[
"TXNRD1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idarubicin"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idarubicin"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
]
]
] |
Arsenic trioxide (Compound) binds IKBKB (Gene) and IKBKB (Gene) is upregulated by Idarubicin (Compound)
Arsenic trioxide (Compound) binds TXNRD1 (Gene) and TXNRD1 (Gene) is downregulated by Idarubicin (Compound)
Arsenic trioxide may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Idarubicin
Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Idarubicin
Arsenic trioxide may lead to a major life threatening interaction when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Arsenic trioxide may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Arsenic trioxide may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Idarubicin
|
DB00855
|
DB05239
| 213
| 866
|
[
"DDInter72",
"DDInter425"
] |
Aminolevulinic acid
|
Cobimetinib
|
A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]
|
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.
|
Major
| 2
|
[
[
[
213,
25,
866
]
],
[
[
213,
25,
33
],
[
33,
24,
866
]
],
[
[
213,
25,
785
],
[
785,
63,
866
]
],
[
[
213,
36,
842
],
[
842,
24,
866
]
],
[
[
213,
64,
1101
],
[
1101,
24,
866
]
],
[
[
213,
64,
1419
],
[
1419,
25,
866
]
],
[
[
213,
25,
1040
],
[
1040,
64,
866
]
],
[
[
213,
25,
33
],
[
33,
24,
214
],
[
214,
63,
866
]
],
[
[
213,
25,
785
],
[
785,
63,
1051
],
[
1051,
24,
866
]
],
[
[
213,
36,
842
],
[
842,
24,
33
],
[
33,
24,
866
]
]
] |
[
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capmatinib"
],
[
"Capmatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Aminolevulinic acid",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Methyl aminolevulinate"
],
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capmatinib"
],
[
"Capmatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Aminolevulinic acid",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Methyl aminolevulinate"
],
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
]
] |
Aminolevulinic acid may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Aminolevulinic acid may lead to a major life threatening interaction when taken with Capmatinib and Capmatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Aminolevulinic acid (Compound) resembles Methyl aminolevulinate (Compound) and Aminolevulinic acid may lead to a major life threatening interaction when taken with Methyl aminolevulinate and Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Aminolevulinic acid may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Aminolevulinic acid may lead to a major life threatening interaction when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Cobimetinib
Aminolevulinic acid may lead to a major life threatening interaction when taken with Dabrafenib and Dabrafenib may lead to a major life threatening interaction when taken with Cobimetinib
Aminolevulinic acid may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Aminolevulinic acid may lead to a major life threatening interaction when taken with Capmatinib and Capmatinib may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Aminolevulinic acid (Compound) resembles Methyl aminolevulinate (Compound) and Aminolevulinic acid may lead to a major life threatening interaction when taken with Methyl aminolevulinate and Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
|
DB01115
|
DB08865
| 336
| 1,593
|
[
"DDInter1291",
"DDInter448"
] |
Nifedipine
|
Crizotinib
|
Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is [amlodipine]. Nifedipine was granted FDA approval on 31 December 1981.
|
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.
|
Moderate
| 1
|
[
[
[
336,
24,
1593
]
],
[
[
336,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
336,
18,
8992
],
[
8992,
46,
1593
]
],
[
[
336,
7,
8386
],
[
8386,
57,
1593
]
],
[
[
336,
18,
10375
],
[
10375,
57,
1593
]
],
[
[
336,
21,
29093
],
[
29093,
60,
1593
]
],
[
[
336,
24,
283
],
[
283,
62,
1593
]
],
[
[
336,
23,
466
],
[
466,
62,
1593
]
],
[
[
336,
63,
883
],
[
883,
24,
1593
]
],
[
[
336,
24,
1409
],
[
1409,
24,
1593
]
]
] |
[
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Nifedipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Nifedipine",
"{u} (Compound) downregulates {v} (Gene)",
"GLRX"
],
[
"GLRX",
"{u} (Gene) is upregulated by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Nifedipine",
"{u} (Compound) upregulates {v} (Gene)",
"MTHFD2"
],
[
"MTHFD2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Nifedipine",
"{u} (Compound) downregulates {v} (Gene)",
"RPS4Y1"
],
[
"RPS4Y1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Nifedipine",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Crizotinib"
]
],
[
[
"Nifedipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Crizotinib"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
]
] |
Nifedipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Nifedipine (Compound) downregulates GLRX (Gene) and GLRX (Gene) is upregulated by Crizotinib (Compound)
Nifedipine (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Crizotinib (Compound)
Nifedipine (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Crizotinib (Compound)
Nifedipine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Nifedipine may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
|
DB00387
|
DB00405
| 1,386
| 128
|
[
"DDInter1528",
"DDInter517"
] |
Procyclidine
|
Dexbrompheniramine
|
A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.
|
Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.
|
Moderate
| 1
|
[
[
[
1386,
24,
128
]
],
[
[
1386,
24,
662
],
[
662,
63,
128
]
],
[
[
1386,
63,
1089
],
[
1089,
24,
128
]
],
[
[
1386,
40,
456
],
[
456,
63,
128
]
],
[
[
1386,
40,
1105
],
[
1105,
24,
128
]
],
[
[
1386,
35,
1192
],
[
1192,
63,
128
]
],
[
[
1386,
25,
1621
],
[
1621,
64,
128
]
],
[
[
1386,
63,
1594
],
[
1594,
35,
128
]
],
[
[
1386,
24,
662
],
[
662,
35,
1376
],
[
1376,
63,
128
]
],
[
[
1386,
24,
1376
],
[
1376,
74,
662
],
[
662,
63,
128
]
]
] |
[
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipratropium"
],
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Procyclidine",
"{u} (Compound) resembles {v} (Compound)",
"Biperiden"
],
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Procyclidine",
"{u} (Compound) resembles {v} (Compound)",
"Trihexyphenidyl"
],
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Procyclidine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Procyclidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
]
] |
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Ipratropium and Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Procyclidine (Compound) resembles Biperiden (Compound) and Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Procyclidine (Compound) resembles Trihexyphenidyl (Compound) and Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Procyclidine (Compound) resembles Glycopyrronium (Compound) and Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Procyclidine may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Dexbrompheniramine
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Dexbrompheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Diphenhydramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Carbinoxamine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
|
DB00563
|
DB00675
| 663
| 888
|
[
"DDInter1174",
"DDInter1744"
] |
Methotrexate
|
Tamoxifen
|
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953.
|
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977.
|
Moderate
| 1
|
[
[
[
663,
24,
888
]
],
[
[
663,
5,
11579
],
[
11579,
44,
888
]
],
[
[
663,
6,
4973
],
[
4973,
45,
888
]
],
[
[
663,
7,
10248
],
[
10248,
46,
888
]
],
[
[
663,
18,
9650
],
[
9650,
46,
888
]
],
[
[
663,
18,
10780
],
[
10780,
57,
888
]
],
[
[
663,
7,
3887
],
[
3887,
57,
888
]
],
[
[
663,
21,
28701
],
[
28701,
60,
888
]
],
[
[
663,
24,
1247
],
[
1247,
62,
888
]
],
[
[
663,
24,
1627
],
[
1627,
63,
888
]
]
] |
[
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Methotrexate",
"{u} (Compound) treats {v} (Disease)",
"breast cancer"
],
[
"breast cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Methotrexate",
"{u} (Compound) upregulates {v} (Gene)",
"FAM63A"
],
[
"FAM63A",
"{u} (Gene) is upregulated by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Methotrexate",
"{u} (Compound) downregulates {v} (Gene)",
"HMGCS1"
],
[
"HMGCS1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Methotrexate",
"{u} (Compound) downregulates {v} (Gene)",
"CCNB2"
],
[
"CCNB2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Methotrexate",
"{u} (Compound) upregulates {v} (Gene)",
"PRSS23"
],
[
"PRSS23",
"{u} (Gene) is downregulated by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Discomfort"
],
[
"Discomfort",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tamoxifen"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
]
] |
Methotrexate (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Tamoxifen (Compound)
Methotrexate (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Tamoxifen (Compound)
Methotrexate (Compound) upregulates FAM63A (Gene) and FAM63A (Gene) is upregulated by Tamoxifen (Compound)
Methotrexate (Compound) downregulates HMGCS1 (Gene) and HMGCS1 (Gene) is upregulated by Tamoxifen (Compound)
Methotrexate (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is downregulated by Tamoxifen (Compound)
Methotrexate (Compound) upregulates PRSS23 (Gene) and PRSS23 (Gene) is downregulated by Tamoxifen (Compound)
Methotrexate (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Tamoxifen (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Tamoxifen
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen
|
DB00526
|
DB01229
| 1,555
| 973
|
[
"DDInter1355",
"DDInter1378"
] |
Oxaliplatin
|
Paclitaxel (protein-bound)
|
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The
|
Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements.
|
Moderate
| 1
|
[
[
[
1555,
24,
973
]
],
[
[
1555,
24,
310
],
[
310,
63,
973
]
],
[
[
1555,
6,
5912
],
[
5912,
45,
973
]
],
[
[
1555,
25,
945
],
[
945,
23,
973
]
],
[
[
1555,
24,
872
],
[
872,
23,
973
]
],
[
[
1555,
64,
1176
],
[
1176,
23,
973
]
],
[
[
1555,
63,
134
],
[
134,
24,
973
]
],
[
[
1555,
25,
762
],
[
762,
63,
973
]
],
[
[
1555,
24,
147
],
[
147,
24,
973
]
],
[
[
1555,
25,
33
],
[
33,
24,
973
]
]
] |
[
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Oxaliplatin",
"{u} (Compound) binds {v} (Gene)",
"ABCC2"
],
[
"ABCC2",
"{u} (Gene) is bound by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bepridil"
],
[
"Bepridil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
]
] |
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Oxaliplatin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Paclitaxel (Compound)
Oxaliplatin may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Paclitaxel
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Paclitaxel
Oxaliplatin may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Paclitaxel
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Oxaliplatin may lead to a major life threatening interaction when taken with Bepridil and Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Oxaliplatin may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
|
DB01377
|
DB09104
| 1,283
| 286
|
[
"DDInter1119",
"DDInter1118"
] |
Magnesium oxide
|
Magnesium hydroxide
|
Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses.
|
Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers).
|
Moderate
| 1
|
[
[
[
1283,
24,
286
]
],
[
[
1283,
23,
481
],
[
481,
23,
286
]
],
[
[
1283,
62,
820
],
[
820,
23,
286
]
],
[
[
1283,
63,
633
],
[
633,
24,
286
]
],
[
[
1283,
24,
1487
],
[
1487,
24,
286
]
],
[
[
1283,
24,
972
],
[
972,
63,
286
]
],
[
[
1283,
23,
9
],
[
9,
24,
286
]
],
[
[
1283,
62,
891
],
[
891,
24,
286
]
],
[
[
1283,
25,
241
],
[
241,
64,
286
]
],
[
[
1283,
64,
1231
],
[
1231,
25,
286
]
]
] |
[
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quazepam"
],
[
"Quazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisdexamfetamine"
],
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Choline salicylate"
],
[
"Choline salicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methotrimeprazine"
],
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Magnesium oxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
],
[
"Erdafitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Magnesium oxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolevamer"
],
[
"Tolevamer",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Magnesium hydroxide"
]
]
] |
Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Quazepam and Quazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Lisdexamfetamine and Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate and Choline salicylate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Methotrimeprazine and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Magnesium oxide may lead to a major life threatening interaction when taken with Erdafitinib and Erdafitinib may lead to a major life threatening interaction when taken with Magnesium hydroxide
Magnesium oxide may lead to a major life threatening interaction when taken with Tolevamer and Tolevamer may lead to a major life threatening interaction when taken with Magnesium hydroxide
|
DB00006
|
DB06186
| 942
| 1,439
|
[
"DDInter217",
"DDInter969"
] |
Bivalirudin
|
Ipilimumab
|
Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.
|
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approval on 25 March 2011.
|
Major
| 2
|
[
[
[
942,
25,
1439
]
],
[
[
942,
25,
1468
],
[
1468,
63,
1439
]
],
[
[
942,
25,
4
],
[
4,
24,
1439
]
],
[
[
942,
25,
1409
],
[
1409,
64,
1439
]
],
[
[
942,
25,
202
],
[
202,
25,
1439
]
],
[
[
942,
64,
1578
],
[
1578,
25,
1439
]
],
[
[
942,
25,
1468
],
[
1468,
63,
912
],
[
912,
24,
1439
]
],
[
[
942,
25,
1409
],
[
1409,
24,
1412
],
[
1412,
63,
1439
]
],
[
[
942,
25,
235
],
[
235,
64,
1486
],
[
1486,
24,
1439
]
],
[
[
942,
64,
1578
],
[
1578,
25,
1468
],
[
1468,
63,
1439
]
]
] |
[
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ipilimumab"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ipilimumab"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ardeparin"
],
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ipilimumab"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ipilimumab"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
],
[
"Calaspargase pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
]
] |
Bivalirudin may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Bivalirudin may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Bivalirudin may lead to a major life threatening interaction when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Ipilimumab
Bivalirudin may lead to a major life threatening interaction when taken with Ardeparin and Ardeparin may lead to a major life threatening interaction when taken with Ipilimumab
Bivalirudin may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Ipilimumab
Bivalirudin may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Bivalirudin may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Bivalirudin may lead to a major life threatening interaction when taken with Desirudin and Desirudin may lead to a major life threatening interaction when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Bivalirudin may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
|
DB00539
|
DB06448
| 11
| 171
|
[
"DDInter1837",
"DDInter1087"
] |
Toremifene
|
Lonafarnib
|
Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.
|
Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.[A224379, A224394] Lonafarnib is a farnesyl transferase (FTase) inhibitor (FTI), which reduces the farnesylation of numerous cellular proteins, including progerin; as progerin farnesylation is important for localization to the nuclear membrane, lonafarnib inhibits progerin accumulation and improves symptoms in HGPS patients.[A224379, A224414, A224419, L23414] Merck originally developed Lonafarnib and subsequently licensed it to Eiger Biopharmaceuticals Inc., which currently markets it under the trademark ZOKINVY™.[L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved treatment for HGPS and other related progeroid laminopathies.[L23414, L23549]
|
Major
| 2
|
[
[
[
11,
25,
171
]
],
[
[
11,
36,
888
],
[
888,
24,
171
]
],
[
[
11,
23,
112
],
[
112,
24,
171
]
],
[
[
11,
64,
1424
],
[
1424,
24,
171
]
],
[
[
11,
63,
1051
],
[
1051,
24,
171
]
],
[
[
11,
25,
1151
],
[
1151,
24,
171
]
],
[
[
11,
24,
98
],
[
98,
63,
171
]
],
[
[
11,
25,
868
],
[
868,
63,
171
]
],
[
[
11,
24,
86
],
[
86,
24,
171
]
],
[
[
11,
25,
129
],
[
129,
64,
171
]
]
] |
[
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
],
[
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
]
] |
Toremifene (Compound) resembles Tamoxifen (Compound) and Toremifene may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Toremifene may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Toremifene may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Toremifene may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Toremifene may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Lonafarnib
|
DB00810
|
DB11130
| 456
| 407
|
[
"DDInter211",
"DDInter1344"
] |
Biperiden
|
Opium
|
A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.
|
Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papaver somniferum_, which is more known as poppies. This plant is an integrant of the Papaveraceae family, and it is characterized by solitary leaves and capsulated fruits. Therefore, opium is a sticky brown resin obtained by collecting and drying the latex that exudes from the poppy pods. Once extracted, opium contains two main groups of alkaloids; the psychoactive constituents which are in the category of phenanthrenes and alkaloids that have no central nervous system effect in the category of isoquinolines. Morphine is the most prevalent and principal alkaloid in opium, and it is responsible for most of the harmful effects of opium. Opium has gradually been superseded by a variety of synthetic opioids and general anesthetics. Some of the isolated derivatives of opium are morphine, noscapine, strychnine, veratrine, colchicine, codeine, and quinine. Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered. There is some legal production of opium in different countries for the obtention of alkaloids by extraction.
|
Moderate
| 1
|
[
[
[
456,
24,
407
]
],
[
[
456,
63,
662
],
[
662,
24,
407
]
],
[
[
456,
24,
104
],
[
104,
24,
407
]
],
[
[
456,
1,
1386
],
[
1386,
24,
407
]
],
[
[
456,
24,
1609
],
[
1609,
63,
407
]
],
[
[
456,
63,
662
],
[
662,
63,
558
],
[
558,
24,
407
]
],
[
[
456,
24,
104
],
[
104,
24,
409
],
[
409,
24,
407
]
],
[
[
456,
24,
849
],
[
849,
63,
409
],
[
409,
24,
407
]
],
[
[
456,
1,
1386
],
[
1386,
24,
662
],
[
662,
24,
407
]
],
[
[
456,
63,
1594
],
[
1594,
24,
558
],
[
558,
24,
407
]
]
] |
[
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Biperiden",
"{u} (Compound) resembles {v} (Compound)",
"Procyclidine"
],
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Biperiden",
"{u} (Compound) resembles {v} (Compound)",
"Procyclidine"
],
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
]
] |
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Biperiden (Compound) resembles Procyclidine (Compound) and Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Zolpidem and Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Opium
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Biperiden (Compound) resembles Procyclidine (Compound) and Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Zolpidem and Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Opium
|
DB01133
|
DB06792
| 1,104
| 1,606
|
[
"DDInter1808",
"DDInter1023"
] |
Tiludronic acid
|
Lanthanum carbonate
|
Tiludronate, or (4-chlorophenyl)thio-methylene-1,1-bisphosphonate, is a first generation bisphosphonate similar to [etidronic acid] and [clodronic acid].[A1923,A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone. Tiludronic acid was granted FDA approval on 7 March 1997.
|
Lanthanum carbonate is a phosphate binder commonly used in clinical practice. It is marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals. It is the largest of all pills filled in community pharmacies. Sometimes patients forget that Fosrenol is not swallowed whole, but instead should be chewed. This has led to severe choking. It is prescribed for treating high phosphate levels, mainly found in patients with chronic kidney disease. Lanthanum should be taken with meals and binds to phosphate in the diet, preventing phosphate absorption in the intestine.
|
Moderate
| 1
|
[
[
[
1104,
24,
1606
]
],
[
[
1104,
24,
428
],
[
428,
63,
1606
]
],
[
[
1104,
24,
1596
],
[
1596,
24,
1606
]
],
[
[
1104,
24,
428
],
[
428,
63,
943
],
[
943,
63,
1606
]
],
[
[
1104,
5,
11658
],
[
11658,
44,
1485
],
[
1485,
24,
1606
]
],
[
[
1104,
24,
1596
],
[
1596,
24,
943
],
[
943,
63,
1606
]
],
[
[
1104,
24,
428
],
[
428,
63,
1152
],
[
1152,
24,
1606
]
],
[
[
1104,
6,
4139
],
[
4139,
45,
1485
],
[
1485,
24,
1606
]
],
[
[
1104,
6,
3150
],
[
3150,
46,
1096
],
[
1096,
24,
1606
]
],
[
[
1104,
54,
19210
],
[
19210,
15,
1485
],
[
1485,
24,
1606
]
]
] |
[
[
[
"Tiludronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
]
],
[
[
"Tiludronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
],
[
"Ferrous fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
]
],
[
[
"Tiludronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
],
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
]
],
[
[
"Tiludronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
],
[
"Ferrous fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
],
[
"Sarecycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
]
],
[
[
"Tiludronic acid",
"{u} (Compound) treats {v} (Disease)",
"Paget's disease of bone"
],
[
"Paget's disease of bone",
"{u} (Disease) is treated by {v} (Compound)",
"Alendronic acid"
],
[
"Alendronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
]
],
[
[
"Tiludronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
],
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
],
[
"Sarecycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
]
],
[
[
"Tiludronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
],
[
"Ferrous fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
]
],
[
[
"Tiludronic acid",
"{u} (Compound) binds {v} (Gene)",
"ATP6V1A"
],
[
"ATP6V1A",
"{u} (Gene) is bound by {v} (Compound)",
"Alendronic acid"
],
[
"Alendronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
]
],
[
[
"Tiludronic acid",
"{u} (Compound) binds {v} (Gene)",
"PTPN1"
],
[
"PTPN1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
]
],
[
[
"Tiludronic acid",
"{u} (Compound) is included by {v} (Pharmacologic Class)",
"Diphosphonates"
],
[
"Diphosphonates",
"{u} (Pharmacologic Class) includes {v} (Compound)",
"Alendronic acid"
],
[
"Alendronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
]
]
] |
Tiludronic acid may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate
Tiludronic acid may cause a moderate interaction that could exacerbate diseases when taken with Iron and Iron may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate
Tiludronic acid may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate
Tiludronic acid (Compound) treats Paget's disease of bone (Disease) and Paget's disease of bone (Disease) is treated by Alendronic acid (Compound) and Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate
Tiludronic acid may cause a moderate interaction that could exacerbate diseases when taken with Iron and Iron may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate
Tiludronic acid may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate
Tiludronic acid (Compound) binds ATP6V1A (Gene) and ATP6V1A (Gene) is bound by Alendronic acid (Compound) and Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate
Tiludronic acid (Compound) binds PTPN1 (Gene) and PTPN1 (Gene) is upregulated by Mycophenolic acid (Compound) and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate
Tiludronic acid (Compound) is included by Diphosphonates (Pharmacologic Class) and Diphosphonates (Pharmacologic Class) includes Alendronic acid (Compound) and Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate
|
DB00023
|
DB01261
| 305
| 170
|
[
"DDInter127",
"DDInter1679"
] |
Asparaginase Escherichia coli
|
Sitagliptin
|
Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997]. L-asparaginase of _E. coli_ is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections. Therapeutic L-asparaginase from _E. coli_ works by depleting the levels
|
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006.
|
Moderate
| 1
|
[
[
[
305,
24,
170
]
],
[
[
305,
24,
52
],
[
52,
62,
170
]
],
[
[
305,
24,
1638
],
[
1638,
24,
170
]
],
[
[
305,
24,
1154
],
[
1154,
63,
170
]
],
[
[
305,
25,
1510
],
[
1510,
63,
170
]
],
[
[
305,
25,
695
],
[
695,
24,
170
]
],
[
[
305,
25,
1101
],
[
1101,
25,
170
]
],
[
[
305,
24,
52
],
[
52,
62,
1103
],
[
1103,
23,
170
]
],
[
[
305,
24,
1638
],
[
1638,
21,
28850
],
[
28850,
60,
170
]
],
[
[
305,
24,
1179
],
[
1179,
23,
1103
],
[
1103,
23,
170
]
]
] |
[
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
],
[
"Dulaglutide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sitagliptin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sitagliptin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
],
[
"Dulaglutide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sitagliptin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
[
"Trandolapril",
"{u} (Compound) causes {v} (Side Effect)",
"Back pain"
],
[
"Back pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sitagliptin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sitagliptin"
]
]
] |
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a minor interaction that can limit clinical effects when taken with Sitagliptin
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Sitagliptin
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Sitagliptin
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Sitagliptin (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Sitagliptin
|
DB01211
|
DB01319
| 609
| 34
|
[
"DDInter393",
"DDInter777"
] |
Clarithromycin
|
Fosamprenavir
|
Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
|
Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.
|
Minor
| 0
|
[
[
[
609,
23,
34
]
],
[
[
609,
62,
1091
],
[
1091,
40,
34
]
],
[
[
609,
6,
8374
],
[
8374,
45,
34
]
],
[
[
609,
21,
29062
],
[
29062,
60,
34
]
],
[
[
609,
24,
466
],
[
466,
62,
34
]
],
[
[
609,
24,
792
],
[
792,
63,
34
]
],
[
[
609,
63,
1144
],
[
1144,
24,
34
]
],
[
[
609,
24,
1021
],
[
1021,
24,
34
]
],
[
[
609,
25,
868
],
[
868,
63,
34
]
],
[
[
609,
64,
1424
],
[
1424,
24,
34
]
]
] |
[
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} (Compound) resembles {v} (Compound)",
"Fosamprenavir"
]
],
[
[
"Clarithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Fosamprenavir"
]
],
[
[
"Clarithromycin",
"{u} (Compound) causes {v} (Side Effect)",
"Neutropenia"
],
[
"Neutropenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fosamprenavir"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
],
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
]
] |
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Amprenavir and Amprenavir (Compound) resembles Fosamprenavir (Compound)
Clarithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fosamprenavir (Compound)
Clarithromycin (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Fosamprenavir (Compound)
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fosamprenavir
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir
Clarithromycin may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir
Clarithromycin may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir
|
DB00959
|
DB04868
| 1,486
| 478
|
[
"DDInter1191",
"DDInter1293"
] |
Methylprednisolone
|
Nilotinib
|
Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.
|
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.
|
Moderate
| 1
|
[
[
[
1486,
24,
478
]
],
[
[
1486,
10,
11555
],
[
11555,
44,
478
]
],
[
[
1486,
6,
4973
],
[
4973,
45,
478
]
],
[
[
1486,
18,
5057
],
[
5057,
46,
478
]
],
[
[
1486,
7,
4759
],
[
4759,
46,
478
]
],
[
[
1486,
6,
1899
],
[
1899,
46,
478
]
],
[
[
1486,
21,
28963
],
[
28963,
60,
478
]
],
[
[
1486,
62,
307
],
[
307,
23,
478
]
],
[
[
1486,
24,
1040
],
[
1040,
63,
478
]
],
[
[
1486,
63,
84
],
[
84,
24,
478
]
]
] |
[
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) palliates {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) downregulates {v} (Gene)",
"IL1B"
],
[
"IL1B",
"{u} (Gene) is upregulated by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) upregulates {v} (Gene)",
"SERPINA3"
],
[
"SERPINA3",
"{u} (Gene) is upregulated by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) binds {v} (Gene)",
"NR3C1"
],
[
"NR3C1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) causes {v} (Side Effect)",
"Anxiety"
],
[
"Anxiety",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Methylprednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nisoldipine"
],
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
]
] |
Methylprednisolone (Compound) palliates hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Nilotinib (Compound)
Methylprednisolone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nilotinib (Compound)
Methylprednisolone (Compound) downregulates IL1B (Gene) and IL1B (Gene) is upregulated by Nilotinib (Compound)
Methylprednisolone (Compound) upregulates SERPINA3 (Gene) and SERPINA3 (Gene) is upregulated by Nilotinib (Compound)
Methylprednisolone (Compound) binds NR3C1 (Gene) and NR3C1 (Gene) is upregulated by Nilotinib (Compound)
Methylprednisolone (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Nisoldipine and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
|
DB01030
|
DB01101
| 869
| 60
|
[
"DDInter1835",
"DDInter285"
] |
Topotecan
|
Capecitabine
|
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
|
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
|
Moderate
| 1
|
[
[
[
869,
24,
60
]
],
[
[
869,
7,
5182
],
[
5182,
45,
60
]
],
[
[
869,
7,
6952
],
[
6952,
46,
60
]
],
[
[
869,
21,
28701
],
[
28701,
60,
60
]
],
[
[
869,
23,
872
],
[
872,
62,
60
]
],
[
[
869,
62,
1176
],
[
1176,
23,
60
]
],
[
[
869,
24,
309
],
[
309,
62,
60
]
],
[
[
869,
23,
246
],
[
246,
23,
60
]
],
[
[
869,
63,
147
],
[
147,
23,
60
]
],
[
[
869,
24,
810
],
[
810,
63,
60
]
]
] |
[
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Topotecan",
"{u} (Compound) upregulates {v} (Gene)",
"CES1"
],
[
"CES1",
"{u} (Gene) is bound by {v} (Compound)",
"Capecitabine"
]
],
[
[
"Topotecan",
"{u} (Compound) upregulates {v} (Gene)",
"MCOLN1"
],
[
"MCOLN1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Capecitabine"
]
],
[
[
"Topotecan",
"{u} (Compound) causes {v} (Side Effect)",
"Discomfort"
],
[
"Discomfort",
"{u} (Side Effect) is caused by {v} (Compound)",
"Capecitabine"
]
],
[
[
"Topotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
]
],
[
[
"Topotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
"Ixabepilone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
]
],
[
[
"Topotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
],
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
]
] |
Topotecan (Compound) upregulates CES1 (Gene) and CES1 (Gene) is bound by Capecitabine (Compound)
Topotecan (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Capecitabine (Compound)
Topotecan (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Capecitabine (Compound)
Topotecan may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Topotecan may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Topotecan may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine
|
DB00490
|
DB06691
| 946
| 849
|
[
"DDInter254",
"DDInter1155"
] |
Buspirone
|
Mepyramine
|
Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs. Unlike many drugs used to treat anxiety, buspirone does not exhibit anticonvulsant, sedative, hypnotic, and muscle-relaxant properties. Due to these characteristics, buspirone been termed 'anxioselective'. First synthesized in 1968 then patented in 1975, it is commonly marketed under the brand name Buspar®. Buspirone was first approved in 1986 by the FDA and has been used to treat anxiety disorders, such as generalized anxiety disorder (GAD), and relieve symptoms of anxiety
|
Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions.
|
Moderate
| 1
|
[
[
[
946,
24,
849
]
],
[
[
946,
63,
1594
],
[
1594,
24,
849
]
],
[
[
946,
24,
272
],
[
272,
24,
849
]
],
[
[
946,
6,
12523
],
[
12523,
45,
849
]
],
[
[
946,
24,
407
],
[
407,
63,
849
]
],
[
[
946,
64,
475
],
[
475,
24,
849
]
],
[
[
946,
25,
1053
],
[
1053,
24,
849
]
],
[
[
946,
24,
662
],
[
662,
35,
849
]
],
[
[
946,
63,
1594
],
[
1594,
1,
11775
],
[
11775,
40,
849
]
],
[
[
946,
24,
272
],
[
272,
1,
11775
],
[
11775,
40,
849
]
]
] |
[
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Buspirone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Mepyramine"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Buspirone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Buspirone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound)",
"Chloropyramine"
],
[
"Chloropyramine",
"{u} (Compound) resembles {v} (Compound)",
"Mepyramine"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Chloropyramine"
],
[
"Chloropyramine",
"{u} (Compound) resembles {v} (Compound)",
"Mepyramine"
]
]
] |
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Buspirone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound)
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Buspirone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Buspirone may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mepyramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Chloropyramine (Compound) and Chloropyramine (Compound) resembles Mepyramine (Compound)
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) resembles Chloropyramine (Compound) and Chloropyramine (Compound) resembles Mepyramine (Compound)
|
DB00621
|
DB01125
| 1,026
| 279
|
[
"DDInter1357",
"DDInter98"
] |
Oxandrolone
|
Anisindione
|
A synthetic hormone with anabolic and androgenic properties.
|
Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver.
|
Major
| 2
|
[
[
[
1026,
25,
279
]
],
[
[
1026,
63,
175
],
[
175,
24,
279
]
],
[
[
1026,
24,
1220
],
[
1220,
63,
279
]
],
[
[
1026,
24,
1411
],
[
1411,
24,
279
]
],
[
[
1026,
25,
1510
],
[
1510,
63,
279
]
],
[
[
1026,
25,
1377
],
[
1377,
24,
279
]
],
[
[
1026,
63,
1512
],
[
1512,
25,
279
]
],
[
[
1026,
63,
175
],
[
175,
63,
1647
],
[
1647,
23,
279
]
],
[
[
1026,
63,
912
],
[
912,
24,
1647
],
[
1647,
23,
279
]
],
[
[
1026,
24,
1220
],
[
1220,
63,
1647
],
[
1647,
23,
279
]
]
] |
[
[
[
"Oxandrolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
]
],
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Oxandrolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Oxandrolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
]
],
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Anisindione"
]
],
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Anisindione"
]
],
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Anisindione"
]
]
] |
Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Oxandrolone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Oxandrolone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Anisindione
Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Anisindione
Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Anisindione
Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Anisindione
|
DB01191
|
DB04932
| 1,039
| 1,564
|
[
"DDInter518",
"DDInter491"
] |
Dexfenfluramine
|
Defibrotide
|
Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn.
|
Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a variety of countries. In the USA it is was approved in March, 2016 as Defitelio.
|
Moderate
| 1
|
[
[
[
1039,
24,
1564
]
],
[
[
1039,
63,
914
],
[
914,
24,
1564
]
],
[
[
1039,
64,
1100
],
[
1100,
24,
1564
]
],
[
[
1039,
25,
41
],
[
41,
63,
1564
]
],
[
[
1039,
24,
885
],
[
885,
24,
1564
]
],
[
[
1039,
25,
1237
],
[
1237,
24,
1564
]
],
[
[
1039,
63,
1347
],
[
1347,
25,
1564
]
],
[
[
1039,
24,
283
],
[
283,
64,
1564
]
],
[
[
1039,
24,
500
],
[
500,
25,
1564
]
],
[
[
1039,
25,
39
],
[
39,
64,
1564
]
]
] |
[
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diflunisal"
],
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
]
] |
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Dexfenfluramine may lead to a major life threatening interaction when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Dexfenfluramine may lead to a major life threatening interaction when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Dexfenfluramine may lead to a major life threatening interaction when taken with Clomipramine and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Defibrotide
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Defibrotide
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin and Enoxaparin may lead to a major life threatening interaction when taken with Defibrotide
Dexfenfluramine may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Defibrotide
|
DB00262
|
DB06674
| 552
| 908
|
[
"DDInter302",
"DDInter837"
] |
Carmustine
|
Golimumab
|
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
|
Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
|
Major
| 2
|
[
[
[
552,
25,
908
]
],
[
[
552,
63,
1461
],
[
1461,
23,
908
]
],
[
[
552,
24,
697
],
[
697,
24,
908
]
],
[
[
552,
24,
200
],
[
200,
63,
908
]
],
[
[
552,
63,
66
],
[
66,
24,
908
]
],
[
[
552,
24,
450
],
[
450,
25,
908
]
],
[
[
552,
25,
334
],
[
334,
64,
908
]
],
[
[
552,
24,
385
],
[
385,
64,
908
]
],
[
[
552,
25,
770
],
[
770,
25,
908
]
],
[
[
552,
64,
581
],
[
581,
25,
908
]
]
] |
[
[
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Golimumab"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
],
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isatuximab"
],
[
"Isatuximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
]
] |
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Golimumab
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide may lead to a major life threatening interaction when taken with Golimumab
Carmustine may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen and Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Golimumab
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab and Isatuximab may lead to a major life threatening interaction when taken with Golimumab
Carmustine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Golimumab
Carmustine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Golimumab
|
DB00862
|
DB01001
| 1,005
| 688
|
[
"DDInter1918",
"DDInter1632"
] |
Vardenafil
|
Salbutamol
|
Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, activating the enzyme guanylate cyclase and increasing the synthesis of cGMP in the smooth muscle cells of the corpus cavernosum. PDE5 inhibitors, such as vardenafil, inhibit the degradation of cGMP and allow increased blood flow into the penis, resulting in an erection.[A258303,L45563,L45568]. Compared to [sildenafil] and [tadalafil], vardenafil is a more potent inhibitor of PDE5; however, its selectivity for other PDE isoforms is lower than the one detected for tadalafil. The FDA approved the use of v
|
Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.[Label,A174379,A174400]
|
Moderate
| 1
|
[
[
[
1005,
24,
688
]
],
[
[
1005,
24,
455
],
[
455,
24,
688
]
],
[
[
1005,
24,
1148
],
[
1148,
63,
688
]
],
[
[
1005,
6,
8374
],
[
8374,
45,
688
]
],
[
[
1005,
21,
28714
],
[
28714,
60,
688
]
],
[
[
1005,
24,
112
],
[
112,
23,
688
]
],
[
[
1005,
63,
543
],
[
543,
24,
688
]
],
[
[
1005,
25,
1069
],
[
1069,
63,
688
]
],
[
[
1005,
64,
1166
],
[
1166,
24,
688
]
],
[
[
1005,
25,
351
],
[
351,
64,
688
]
]
] |
[
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Vardenafil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Salbutamol"
]
],
[
[
"Vardenafil",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Salbutamol"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Vardenafil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Vardenafil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Vardenafil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salbutamol"
]
]
] |
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Vardenafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Salbutamol (Compound)
Vardenafil (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Salbutamol (Compound)
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Salbutamol
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Vardenafil may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Vardenafil may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Vardenafil may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Salbutamol
|
DB00736
|
DB00745
| 660
| 307
|
[
"DDInter676",
"DDInter1236"
] |
Esomeprazole
|
Modafinil
|
Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including,, and, for example.[A177271, F4498] Its efficacy is considered similar to other medications within the PPI class including,,,, and. Esomeprazole is the s-isomer of, which is a racemate of the S- and R-enantiomer. Esomeprazole has been shown to inhibit acid secretion to a similar extent as, without any significant differences between the two compounds _in vitro_. Esome
|
Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA.
|
Moderate
| 1
|
[
[
[
660,
24,
307
]
],
[
[
660,
63,
362
],
[
362,
40,
307
]
],
[
[
660,
24,
1335
],
[
1335,
40,
307
]
],
[
[
660,
6,
10215
],
[
10215,
45,
307
]
],
[
[
660,
21,
28851
],
[
28851,
60,
307
]
],
[
[
660,
25,
1250
],
[
1250,
62,
307
]
],
[
[
660,
63,
883
],
[
883,
23,
307
]
],
[
[
660,
24,
976
],
[
976,
62,
307
]
],
[
[
660,
23,
609
],
[
609,
62,
307
]
],
[
[
660,
62,
168
],
[
168,
23,
307
]
]
] |
[
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
]
],
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
]
],
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
]
],
[
[
"Esomeprazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Modafinil"
]
],
[
[
"Esomeprazole",
"{u} (Compound) causes {v} (Side Effect)",
"Hepatic enzyme increased"
],
[
"Hepatic enzyme increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Modafinil"
]
],
[
[
"Esomeprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
],
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
],
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
],
[
[
"Esomeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
],
[
[
"Esomeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
]
] |
Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Modafinil (Compound)
Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Modafinil (Compound)
Esomeprazole (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Modafinil (Compound)
Esomeprazole (Compound) causes Hepatic enzyme increased (Side Effect) and Hepatic enzyme increased (Side Effect) is caused by Modafinil (Compound)
Esomeprazole may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Modafinil
Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Modafinil
|
DB00400
|
DB00990
| 353
| 1,547
|
[
"DDInter843",
"DDInter705"
] |
Griseofulvin
|
Exemestane
|
An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections.
|
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
|
Moderate
| 1
|
[
[
[
353,
24,
1547
]
],
[
[
353,
63,
380
],
[
380,
24,
1547
]
],
[
[
353,
24,
559
],
[
559,
24,
1547
]
],
[
[
353,
6,
8374
],
[
8374,
45,
1547
]
],
[
[
353,
21,
28757
],
[
28757,
60,
1547
]
],
[
[
353,
24,
192
],
[
192,
63,
1547
]
],
[
[
353,
62,
1101
],
[
1101,
24,
1547
]
],
[
[
353,
63,
380
],
[
380,
24,
891
],
[
891,
40,
1547
]
],
[
[
353,
24,
559
],
[
559,
24,
891
],
[
891,
40,
1547
]
],
[
[
353,
6,
8374
],
[
8374,
45,
891
],
[
891,
40,
1547
]
]
] |
[
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exemestane"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conjugated estrogens"
],
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exemestane"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estrone"
],
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exemestane"
]
],
[
[
"Griseofulvin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Exemestane"
]
],
[
[
"Griseofulvin",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Exemestane"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
],
[
"Esterified estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exemestane"
]
],
[
[
"Griseofulvin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exemestane"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conjugated estrogens"
],
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Exemestane"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estrone"
],
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Exemestane"
]
],
[
[
"Griseofulvin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Exemestane"
]
]
] |
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Exemestane
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Estrone and Estrone may cause a moderate interaction that could exacerbate diseases when taken with Exemestane
Griseofulvin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Exemestane (Compound)
Griseofulvin (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Exemestane (Compound)
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens and Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Exemestane
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Exemestane
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone (Compound) resembles Exemestane (Compound)
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Estrone and Estrone may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone (Compound) resembles Exemestane (Compound)
Griseofulvin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Prednisolone (Compound) and Prednisolone (Compound) resembles Exemestane (Compound)
|
DB00860
|
DB00881
| 891
| 954
|
[
"DDInter1513",
"DDInter1554"
] |
Prednisolone
|
Quinapril
|
Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955.
|
Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. Quinapril was granted FDA approval on 19 November 1991. A combination tablet with [hydrochlorothiazide] was also approved on 28 December 1999.
|
Moderate
| 1
|
[
[
[
891,
24,
954
]
],
[
[
891,
63,
1638
],
[
1638,
1,
954
]
],
[
[
891,
63,
1523
],
[
1523,
40,
954
]
],
[
[
891,
21,
28644
],
[
28644,
60,
954
]
],
[
[
891,
23,
1117
],
[
1117,
62,
954
]
],
[
[
891,
24,
286
],
[
286,
62,
954
]
],
[
[
891,
24,
28
],
[
28,
63,
954
]
],
[
[
891,
40,
251
],
[
251,
24,
954
]
],
[
[
891,
63,
1648
],
[
1648,
24,
954
]
],
[
[
891,
40,
1220
],
[
1220,
63,
954
]
]
] |
[
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
[
"Trandolapril",
"{u} (Compound) resembles {v} (Compound)",
"Quinapril"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
[
"Labetalol",
"{u} (Compound) resembles {v} (Compound)",
"Quinapril"
]
],
[
[
"Prednisolone",
"{u} (Compound) causes {v} (Side Effect)",
"Syncope"
],
[
"Syncope",
"{u} (Side Effect) is caused by {v} (Compound)",
"Quinapril"
]
],
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
],
[
"Sodium bicarbonate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinapril"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinapril"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
]
] |
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Quinapril (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Quinapril (Compound)
Prednisolone (Compound) causes Syncope (Side Effect) and Syncope (Side Effect) is caused by Quinapril (Compound)
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate and Sodium bicarbonate may cause a minor interaction that can limit clinical effects when taken with Quinapril
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Quinapril
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Quinapril
Prednisolone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Quinapril
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Quinapril
Prednisolone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Quinapril
|
DB01041
|
DB01073
| 770
| 1,488
|
[
"DDInter1789",
"DDInter745"
] |
Thalidomide
|
Fludarabine
|
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
|
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
|
Major
| 2
|
[
[
[
770,
25,
1488
]
],
[
[
770,
64,
1426
],
[
1426,
1,
1488
]
],
[
[
770,
5,
11555
],
[
11555,
44,
1488
]
],
[
[
770,
21,
28701
],
[
28701,
60,
1488
]
],
[
[
770,
63,
839
],
[
839,
23,
1488
]
],
[
[
770,
24,
1539
],
[
1539,
62,
1488
]
],
[
[
770,
24,
956
],
[
956,
23,
1488
]
],
[
[
770,
63,
1253
],
[
1253,
24,
1488
]
],
[
[
770,
25,
975
],
[
975,
63,
1488
]
],
[
[
770,
24,
36
],
[
36,
63,
1488
]
]
] |
[
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludarabine"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Azacitidine"
],
[
"Azacitidine",
"{u} (Compound) resembles {v} (Compound)",
"Fludarabine"
]
],
[
[
"Thalidomide",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Fludarabine"
]
],
[
[
"Thalidomide",
"{u} (Compound) causes {v} (Side Effect)",
"Discomfort"
],
[
"Discomfort",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fludarabine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fludarabine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fludarabine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fludarabine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palifermin"
],
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
],
[
"Lurbinectedin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
]
] |
Thalidomide may lead to a major life threatening interaction when taken with Azacitidine and Azacitidine (Compound) resembles Fludarabine (Compound)
Thalidomide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Fludarabine (Compound)
Thalidomide (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Fludarabine (Compound)
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Fludarabine
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Fludarabine
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Fludarabine
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Palifermin and Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine
Thalidomide may lead to a major life threatening interaction when taken with Lurbinectedin and Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine
|
DB00641
|
DB12015
| 467
| 1,033
|
[
"DDInter1675",
"DDInter53"
] |
Simvastatin
|
Alpelisib
|
Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a
|
Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer , are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019. In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.
|
Moderate
| 1
|
[
[
[
467,
24,
1033
]
],
[
[
467,
24,
951
],
[
951,
24,
1033
]
],
[
[
467,
63,
10
],
[
10,
24,
1033
]
],
[
[
467,
25,
1510
],
[
1510,
24,
1033
]
],
[
[
467,
23,
126
],
[
126,
24,
1033
]
],
[
[
467,
74,
1463
],
[
1463,
24,
1033
]
],
[
[
467,
24,
982
],
[
982,
63,
1033
]
],
[
[
467,
64,
1622
],
[
1622,
24,
1033
]
],
[
[
467,
25,
1604
],
[
1604,
25,
1033
]
],
[
[
467,
24,
129
],
[
129,
25,
1033
]
]
] |
[
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Simvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Simvastatin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alpelisib"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alpelisib"
]
]
] |
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Simvastatin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Simvastatin may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Simvastatin (Compound) resembles Lovastatin (Compound) and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Simvastatin may lead to a major life threatening interaction when taken with Voriconazole and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Simvastatin may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may lead to a major life threatening interaction when taken with Alpelisib
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Alpelisib
|
DB00379
|
DB05812
| 143
| 1,374
|
[
"DDInter1206",
"DDInter8"
] |
Mexiletine
|
Abiraterone
|
Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.
|
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resistant prostate cancer and hormone-sensitive high-risk metastatic prostate cancer.[L40968, L40193, L47740, L47745] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability and absorption.[A3811, A260835]
|
Moderate
| 1
|
[
[
[
143,
24,
1374
]
],
[
[
143,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
143,
21,
28809
],
[
28809,
60,
1374
]
],
[
[
143,
24,
760
],
[
760,
62,
1374
]
],
[
[
143,
63,
1010
],
[
1010,
24,
1374
]
],
[
[
143,
24,
187
],
[
187,
24,
1374
]
],
[
[
143,
24,
283
],
[
283,
63,
1374
]
],
[
[
143,
24,
1670
],
[
1670,
64,
1374
]
],
[
[
143,
63,
702
],
[
702,
25,
1374
]
],
[
[
143,
24,
478
],
[
478,
25,
1374
]
]
] |
[
[
[
"Mexiletine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Mexiletine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Abiraterone"
]
],
[
[
"Mexiletine",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Abiraterone"
]
],
[
[
"Mexiletine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
]
],
[
[
"Mexiletine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Mexiletine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
],
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Mexiletine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Mexiletine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
]
],
[
[
"Mexiletine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
]
],
[
[
"Mexiletine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
]
]
] |
Mexiletine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Mexiletine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Abiraterone (Compound)
Mexiletine may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Mexiletine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Mexiletine may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone and Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Mexiletine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Mexiletine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may lead to a major life threatening interaction when taken with Abiraterone
Mexiletine may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Abiraterone
Mexiletine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Abiraterone
|
DB00019
|
DB01101
| 1,257
| 60
|
[
"DDInter1405",
"DDInter285"
] |
Pegfilgrastim
|
Capecitabine
|
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of developing febrile neutropenia is less than 20% in many readily used chemotherapy regimens, infections pose risks of hospitalization and mortalities. Due to the relatively short circulating half-life of filgrastim, a 20 kDa PEG moiety was covalently conjugated to the N-terminus of filgrastim (at the methionine residue) to develop longer-acting pegfilgrastim.[A29,A187607] Due to a longer half-life and slower elimination rate than filgrastim
|
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
|
Moderate
| 1
|
[
[
[
1257,
24,
60
]
],
[
[
1257,
24,
309
],
[
309,
62,
60
]
],
[
[
1257,
24,
147
],
[
147,
23,
60
]
],
[
[
1257,
24,
599
],
[
599,
24,
60
]
],
[
[
1257,
24,
4
],
[
4,
63,
60
]
],
[
[
1257,
25,
1064
],
[
1064,
25,
60
]
],
[
[
1257,
24,
770
],
[
770,
25,
60
]
],
[
[
1257,
24,
309
],
[
309,
5,
11579
],
[
11579,
44,
60
]
],
[
[
1257,
24,
599
],
[
599,
24,
309
],
[
309,
62,
60
]
],
[
[
1257,
24,
869
],
[
869,
7,
5182
],
[
5182,
45,
60
]
]
] |
[
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
"Ixabepilone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Pegfilgrastim",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capecitabine"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capecitabine"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
"Ixabepilone",
"{u} (Compound) treats {v} (Disease)",
"breast cancer"
],
[
"breast cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Capecitabine"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
"Ixabepilone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} (Compound) upregulates {v} (Gene)",
"CES1"
],
[
"CES1",
"{u} (Gene) is bound by {v} (Compound)",
"Capecitabine"
]
]
] |
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine
Pegfilgrastim may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Capecitabine
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Capecitabine
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Capecitabine (Compound)
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) upregulates CES1 (Gene) and CES1 (Gene) is bound by Capecitabine (Compound)
|
DB00843
|
DB09073
| 479
| 951
|
[
"DDInter583",
"DDInter1379"
] |
Donepezil
|
Palbociclib
|
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other types of dementia. Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia.[L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia. Though it does not alter the progression of Alzheimer's disease, donepezil is effective in managing the symptoms of its associated dementia.
|
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.
|
Minor
| 0
|
[
[
[
479,
23,
951
]
],
[
[
479,
24,
1476
],
[
1476,
63,
951
]
],
[
[
479,
23,
159
],
[
159,
63,
951
]
],
[
[
479,
62,
600
],
[
600,
24,
951
]
],
[
[
479,
24,
1040
],
[
1040,
24,
951
]
],
[
[
479,
63,
1425
],
[
1425,
24,
951
]
],
[
[
479,
23,
478
],
[
478,
24,
951
]
],
[
[
479,
24,
129
],
[
129,
25,
951
]
],
[
[
479,
23,
609
],
[
609,
25,
951
]
],
[
[
479,
24,
1604
],
[
1604,
64,
951
]
]
] |
[
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Palbociclib"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
],
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
]
] |
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Donepezil may cause a minor interaction that can limit clinical effects when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Donepezil may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Cisapride and Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Donepezil may cause a minor interaction that can limit clinical effects when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Palbociclib
Donepezil may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Palbociclib
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may lead to a major life threatening interaction when taken with Palbociclib
|
DB00331
|
DB01224
| 1,645
| 623
|
[
"DDInter1164",
"DDInter1553"
] |
Metformin
|
Quetiapine
|
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes. Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
|
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine].
|
Moderate
| 1
|
[
[
[
1645,
24,
623
]
],
[
[
1645,
24,
695
],
[
695,
1,
623
]
],
[
[
1645,
18,
4729
],
[
4729,
57,
623
]
],
[
[
1645,
21,
29272
],
[
29272,
60,
623
]
],
[
[
1645,
24,
752
],
[
752,
23,
623
]
],
[
[
1645,
24,
1616
],
[
1616,
63,
623
]
],
[
[
1645,
63,
1179
],
[
1179,
24,
623
]
],
[
[
1645,
24,
1674
],
[
1674,
24,
623
]
],
[
[
1645,
62,
1647
],
[
1647,
24,
623
]
],
[
[
1645,
24,
609
],
[
609,
25,
623
]
]
] |
[
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
]
],
[
[
"Metformin",
"{u} (Compound) downregulates {v} (Gene)",
"EBNA1BP2"
],
[
"EBNA1BP2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Quetiapine"
]
],
[
[
"Metformin",
"{u} (Compound) causes {v} (Side Effect)",
"Accidental injury"
],
[
"Accidental injury",
"{u} (Side Effect) is caused by {v} (Compound)",
"Quetiapine"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quetiapine"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
],
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Metformin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quetiapine"
]
]
] |
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Quetiapine (Compound)
Metformin (Compound) downregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) is downregulated by Quetiapine (Compound)
Metformin (Compound) causes Accidental injury (Side Effect) and Accidental injury (Side Effect) is caused by Quetiapine (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Quetiapine
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Metformin may cause a minor interaction that can limit clinical effects when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Quetiapine
|
DB00911
|
DB05773
| 458
| 1,047
|
[
"DDInter1811",
"DDInter1848"
] |
Tinidazole
|
Trastuzumab emtansine
|
A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections.
|
Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.
|
Moderate
| 1
|
[
[
[
458,
24,
1047
]
],
[
[
458,
64,
1091
],
[
1091,
24,
1047
]
],
[
[
458,
24,
375
],
[
375,
63,
1047
]
],
[
[
458,
24,
1112
],
[
1112,
24,
1047
]
],
[
[
458,
63,
467
],
[
467,
24,
1047
]
],
[
[
458,
40,
112
],
[
112,
24,
1047
]
],
[
[
458,
24,
1468
],
[
1468,
64,
1047
]
],
[
[
458,
63,
126
],
[
126,
25,
1047
]
],
[
[
458,
24,
1377
],
[
1377,
25,
1047
]
],
[
[
458,
64,
1091
],
[
1091,
24,
310
],
[
310,
63,
1047
]
]
] |
[
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Tinidazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Auranofin"
],
[
"Auranofin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Tinidazole",
"{u} (Compound) resembles {v} (Compound)",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Tinidazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
]
] |
Tinidazole may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Auranofin and Auranofin may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Tinidazole (Compound) resembles Metronidazole (Compound) and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may lead to a major life threatening interaction when taken with Trastuzumab emtansine
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Trastuzumab emtansine
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Trastuzumab emtansine
Tinidazole may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
|
DB09065
|
DB12267
| 760
| 1,476
|
[
"DDInter424",
"DDInter233"
] |
Cobicistat
|
Brigatinib
|
Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile.
|
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
|
Major
| 2
|
[
[
[
760,
25,
1476
]
],
[
[
760,
24,
1612
],
[
1612,
23,
1476
]
],
[
[
760,
64,
1135
],
[
1135,
23,
1476
]
],
[
[
760,
63,
168
],
[
168,
23,
1476
]
],
[
[
760,
25,
230
],
[
230,
23,
1476
]
],
[
[
760,
64,
629
],
[
629,
24,
1476
]
],
[
[
760,
25,
951
],
[
951,
24,
1476
]
],
[
[
760,
25,
829
],
[
829,
63,
1476
]
],
[
[
760,
63,
968
],
[
968,
24,
1476
]
],
[
[
760,
62,
1204
],
[
1204,
24,
1476
]
]
] |
[
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brigatinib"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brigatinib"
]
],
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brigatinib"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
],
[
"Relugolix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brigatinib"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ubrogepant"
],
[
"Ubrogepant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oritavancin"
],
[
"Oritavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Cobicistat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ambrisentan"
],
[
"Ambrisentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
]
] |
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Cobicistat may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Cobicistat may lead to a major life threatening interaction when taken with Relugolix and Relugolix may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Cobicistat may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Cobicistat may lead to a major life threatening interaction when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Cobicistat may lead to a major life threatening interaction when taken with Ubrogepant and Ubrogepant may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Oritavancin and Oritavancin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Cobicistat may cause a minor interaction that can limit clinical effects when taken with Ambrisentan and Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
|
DB06772
|
DB09498
| 310
| 810
|
[
"DDInter259",
"DDInter1715"
] |
Cabazitaxel
|
Strontium chloride Sr-89
|
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.
|
Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stages of the disease. It is usually presented mainly in patients with prostatic and breast cancer, as well as in cancer of lung, bladder and thyroid. There has been some cases of apparent tumor regression which has given it a potential tumoricidal effect.
|
Moderate
| 1
|
[
[
[
310,
24,
810
]
],
[
[
310,
63,
1555
],
[
1555,
24,
810
]
],
[
[
310,
24,
1060
],
[
1060,
63,
810
]
],
[
[
310,
24,
350
],
[
350,
24,
810
]
],
[
[
310,
25,
976
],
[
976,
24,
810
]
],
[
[
310,
25,
1259
],
[
1259,
63,
810
]
],
[
[
310,
64,
695
],
[
695,
25,
810
]
],
[
[
310,
63,
1555
],
[
1555,
63,
552
],
[
552,
24,
810
]
],
[
[
310,
24,
1060
],
[
1060,
63,
1555
],
[
1555,
24,
810
]
],
[
[
310,
63,
63
],
[
63,
24,
1555
],
[
1555,
24,
810
]
]
] |
[
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
],
[
"Enfortumab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Cabazitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Cabazitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Cabazitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
],
[
"Enfortumab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
],
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
]
] |
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Cabazitaxel may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Cabazitaxel may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Cabazitaxel may lead to a major life threatening interaction when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Strontium chloride Sr-89
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
|
DB00281
|
DB08912
| 608
| 1,040
|
[
"DDInter1066",
"DDInter462"
] |
Lidocaine
|
Dabrafenib
|
Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L
|
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
|
Minor
| 0
|
[
[
[
608,
23,
1040
]
],
[
[
608,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
608,
18,
15501
],
[
15501,
57,
1040
]
],
[
[
608,
21,
28658
],
[
28658,
60,
1040
]
],
[
[
608,
23,
1101
],
[
1101,
23,
1040
]
],
[
[
608,
24,
481
],
[
481,
24,
1040
]
],
[
[
608,
23,
129
],
[
129,
24,
1040
]
],
[
[
608,
23,
985
],
[
985,
63,
1040
]
],
[
[
608,
63,
494
],
[
494,
24,
1040
]
],
[
[
608,
25,
1327
],
[
1327,
24,
1040
]
]
] |
[
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dabrafenib"
]
],
[
[
"Lidocaine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Lidocaine",
"{u} (Compound) downregulates {v} (Gene)",
"CCDC86"
],
[
"CCDC86",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Lidocaine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dabrafenib"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
],
[
"Quazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Lidocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
]
] |
Lidocaine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Lidocaine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Dabrafenib (Compound)
Lidocaine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Dabrafenib (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Lidocaine may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
|
DB00501
|
DB04908
| 752
| 1,671
|
[
"DDInter380",
"DDInter741"
] |
Cimetidine
|
Flibanserin
|
A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
|
Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin's mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.
|
Moderate
| 1
|
[
[
[
752,
24,
1671
]
],
[
[
752,
23,
1135
],
[
1135,
62,
1671
]
],
[
[
752,
24,
1478
],
[
1478,
63,
1671
]
],
[
[
752,
24,
506
],
[
506,
24,
1671
]
],
[
[
752,
63,
1018
],
[
1018,
24,
1671
]
],
[
[
752,
25,
1213
],
[
1213,
24,
1671
]
],
[
[
752,
23,
222
],
[
222,
24,
1671
]
],
[
[
752,
25,
1250
],
[
1250,
63,
1671
]
],
[
[
752,
64,
322
],
[
322,
24,
1671
]
],
[
[
752,
24,
283
],
[
283,
64,
1671
]
]
] |
[
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Flibanserin"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flibanserin"
]
]
] |
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Flibanserin
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Cimetidine may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Cimetidine may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Cimetidine may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Flibanserin
|
DB08865
|
DB09083
| 1,593
| 880
|
[
"DDInter448",
"DDInter996"
] |
Crizotinib
|
Ivabradine
|
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used
|
Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a "pure" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.
|
Major
| 2
|
[
[
[
1593,
25,
880
]
],
[
[
1593,
63,
480
],
[
480,
24,
880
]
],
[
[
1593,
64,
1478
],
[
1478,
24,
880
]
],
[
[
1593,
24,
159
],
[
159,
63,
880
]
],
[
[
1593,
24,
1040
],
[
1040,
24,
880
]
],
[
[
1593,
25,
1476
],
[
1476,
63,
880
]
],
[
[
1593,
25,
1011
],
[
1011,
24,
880
]
],
[
[
1593,
64,
39
],
[
39,
25,
880
]
],
[
[
1593,
25,
351
],
[
351,
64,
880
]
],
[
[
1593,
25,
384
],
[
384,
25,
880
]
]
] |
[
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
]
] |
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Crizotinib may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Crizotinib may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Crizotinib may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Crizotinib may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Ivabradine
Crizotinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Ivabradine
Crizotinib may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Ivabradine
|
DB01211
|
DB12147
| 609
| 241
|
[
"DDInter393",
"DDInter661"
] |
Clarithromycin
|
Erdafitinib
|
Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
|
In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. [L5956, L5959] At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy [L5956, L5959]. Erdafitinib is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the development of more personalized and precise medicines tailoring to a patient's specific genetic mutation.[L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic tool kit to treat such a prevalent medical condition.
|
Major
| 2
|
[
[
[
609,
25,
241
]
],
[
[
609,
24,
170
],
[
170,
24,
241
]
],
[
[
609,
25,
1456
],
[
1456,
24,
241
]
],
[
[
609,
25,
982
],
[
982,
63,
241
]
],
[
[
609,
64,
1425
],
[
1425,
24,
241
]
],
[
[
609,
63,
1419
],
[
1419,
24,
241
]
],
[
[
609,
62,
1413
],
[
1413,
24,
241
]
],
[
[
609,
24,
1619
],
[
1619,
63,
241
]
],
[
[
609,
24,
286
],
[
286,
25,
241
]
],
[
[
609,
25,
1017
],
[
1017,
25,
241
]
]
] |
[
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fexofenadine"
],
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
]
]
] |
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Clarithromycin may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Clarithromycin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Clarithromycin may lead to a major life threatening interaction when taken with Cisapride and Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Fexofenadine and Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may lead to a major life threatening interaction when taken with Erdafitinib
Clarithromycin may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Erdafitinib
|
DB01599
|
DB13074
| 1,232
| 877
|
[
"DDInter1523",
"DDInter1110"
] |
Probucol
|
Macimorelin
|
A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
|
Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels . Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. Growth hormone (GH) is classically linked with linear growth during childhood. In deficiency of this hormone, AGHD is commonly associated with increased fat mass (particularly in the abdominal region), decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance overtime. In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function . Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone deficiencies . While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection and diagnosis of AGHD. The diagnosis of AGHD requires biochemical confirmation with at least 1 GH stimulation test . Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand. In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability . Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution.
|
Major
| 2
|
[
[
[
1232,
25,
877
]
],
[
[
1232,
62,
112
],
[
112,
23,
877
]
],
[
[
1232,
24,
913
],
[
913,
24,
877
]
],
[
[
1232,
63,
770
],
[
770,
24,
877
]
],
[
[
1232,
63,
485
],
[
485,
25,
877
]
],
[
[
1232,
25,
478
],
[
478,
25,
877
]
],
[
[
1232,
24,
144
],
[
144,
25,
877
]
],
[
[
1232,
25,
982
],
[
982,
64,
877
]
],
[
[
1232,
64,
702
],
[
702,
25,
877
]
],
[
[
1232,
62,
112
],
[
112,
23,
1247
],
[
1247,
23,
877
]
]
] |
[
[
[
"Probucol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Probucol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Macimorelin"
]
],
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Probucol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Probucol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Probucol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Probucol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Macimorelin"
]
]
] |
Probucol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Macimorelin
Probucol may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Macimorelin
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may lead to a major life threatening interaction when taken with Macimorelin
Probucol may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Macimorelin
Probucol may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Macimorelin
Probucol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
|
DB09036
|
DB10276
| 812
| 1,624
|
[
"DDInter1668",
"DDInter1623"
] |
Siltuximab
|
Rotavirus vaccine
|
Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes. It is administered as a 1 hour intravenous infusion every 3 weeks.
|
Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotarix is a live attenuated vaccine containing the 89-12 human strain.[Label] Rotavirus vaccines are 90% effective in protecting against severe rotavirus infection.
|
Major
| 2
|
[
[
[
812,
25,
1624
]
],
[
[
812,
64,
375
],
[
375,
25,
1624
]
],
[
[
812,
63,
58
],
[
58,
25,
1624
]
],
[
[
812,
24,
270
],
[
270,
64,
1624
]
],
[
[
812,
25,
1259
],
[
1259,
64,
1624
]
],
[
[
812,
64,
375
],
[
375,
64,
617
],
[
617,
24,
1624
]
],
[
[
812,
63,
58
],
[
58,
24,
617
],
[
617,
24,
1624
]
],
[
[
812,
24,
270
],
[
270,
63,
617
],
[
617,
24,
1624
]
],
[
[
812,
63,
259
],
[
259,
63,
617
],
[
617,
24,
1624
]
],
[
[
812,
64,
581
],
[
581,
25,
617
],
[
617,
24,
1624
]
]
] |
[
[
[
"Siltuximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Siltuximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Siltuximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Siltuximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Siltuximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rotavirus vaccine"
]
]
] |
Siltuximab may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Rotavirus vaccine
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may lead to a major life threatening interaction when taken with Rotavirus vaccine
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may lead to a major life threatening interaction when taken with Rotavirus vaccine
Siltuximab may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Rotavirus vaccine
Siltuximab may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine
Siltuximab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine
|
DB01021
|
DB11110
| 674
| 603
|
[
"DDInter1861",
"DDInter1115"
] |
Trichlormethiazide
|
Magnesium citrate
|
A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)
|
Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg. It is also considered as an active ingredient in over-the-counter products.
|
Moderate
| 1
|
[
[
[
674,
24,
603
]
],
[
[
674,
25,
57
],
[
57,
24,
603
]
],
[
[
674,
63,
870
],
[
870,
24,
603
]
],
[
[
674,
40,
1326
],
[
1326,
24,
603
]
],
[
[
674,
1,
323
],
[
323,
24,
603
]
],
[
[
674,
62,
1572
],
[
1572,
24,
603
]
],
[
[
674,
24,
1196
],
[
1196,
24,
603
]
],
[
[
674,
64,
1166
],
[
1166,
24,
603
]
],
[
[
674,
24,
1019
],
[
1019,
63,
603
]
],
[
[
674,
25,
57
],
[
57,
64,
789
],
[
789,
24,
603
]
]
] |
[
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Trichlormethiazide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Trichlormethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Diclofenamide"
],
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Trichlormethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Trichlormethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxercalciferol"
],
[
"Doxercalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Trichlormethiazide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Trichlormethiazide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Foscarnet"
],
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
]
] |
Trichlormethiazide may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Trichlormethiazide (Compound) resembles Diclofenamide (Compound) and Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Trichlormethiazide (Compound) resembles Bendroflumethiazide (Compound) and Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Trichlormethiazide may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Doxercalciferol and Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Trichlormethiazide may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Trichlormethiazide may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Foscarnet and Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
|
DB00056
|
DB01030
| 816
| 869
|
[
"DDInter814",
"DDInter1835"
] |
Gemtuzumab ozogamicin
|
Topotecan
|
Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody [FDA Label]. The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death. Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or
|
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
|
Moderate
| 1
|
[
[
[
816,
24,
869
]
],
[
[
816,
23,
872
],
[
872,
62,
869
]
],
[
[
816,
23,
1467
],
[
1467,
23,
869
]
],
[
[
816,
24,
1270
],
[
1270,
63,
869
]
],
[
[
816,
24,
482
],
[
482,
24,
869
]
],
[
[
816,
63,
1184
],
[
1184,
24,
869
]
],
[
[
816,
25,
1064
],
[
1064,
24,
869
]
],
[
[
816,
25,
990
],
[
990,
63,
869
]
],
[
[
816,
64,
1057
],
[
1057,
25,
869
]
],
[
[
816,
25,
676
],
[
676,
64,
869
]
]
] |
[
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Topotecan"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enoxacin"
],
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Topotecan"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
],
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
]
]
] |
Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan
Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Gemtuzumab ozogamicin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Gemtuzumab ozogamicin may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Gemtuzumab ozogamicin may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Topotecan
Gemtuzumab ozogamicin may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Topotecan
|
DB01156
|
DB01577
| 593
| 1,529
|
[
"DDInter252",
"DDInter1161"
] |
Bupropion
|
Metamfetamine
|
Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).[A6399,A178810] Bupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MA
|
Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potential for addiction and abuse. The FDA withdrew its approval for the use of all parenteral drug products containing methamphetamine hydrochloride, a metamfetamine salt.
|
Major
| 2
|
[
[
[
593,
25,
1529
]
],
[
[
593,
64,
939
],
[
939,
40,
1529
]
],
[
[
593,
25,
93
],
[
93,
1,
1529
]
],
[
[
593,
25,
22
],
[
22,
24,
1529
]
],
[
[
593,
25,
1039
],
[
1039,
25,
1529
]
],
[
[
593,
64,
551
],
[
551,
1,
1529
]
],
[
[
593,
25,
633
],
[
633,
40,
1529
]
],
[
[
593,
5,
11585
],
[
11585,
44,
1529
]
],
[
[
593,
6,
7390
],
[
7390,
45,
1529
]
],
[
[
593,
10,
11601
],
[
11601,
49,
1529
]
]
] |
[
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metamfetamine"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Benzphetamine"
],
[
"Benzphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Metamfetamine"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextroamphetamine"
],
[
"Dextroamphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Metamfetamine"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metamfetamine"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenelzine"
],
[
"Phenelzine",
"{u} (Compound) resembles {v} (Compound)",
"Metamfetamine"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lisdexamfetamine"
],
[
"Lisdexamfetamine",
"{u} (Compound) resembles {v} (Compound)",
"Metamfetamine"
]
],
[
[
"Bupropion",
"{u} (Compound) treats {v} (Disease)",
"obesity"
],
[
"obesity",
"{u} (Disease) is treated by {v} (Compound)",
"Metamfetamine"
]
],
[
[
"Bupropion",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
],
[
"SLC6A2",
"{u} (Gene) is bound by {v} (Compound)",
"Metamfetamine"
]
],
[
[
"Bupropion",
"{u} (Compound) palliates {v} (Disease)",
"attention deficit hyperactivity disorder"
],
[
"attention deficit hyperactivity disorder",
"{u} (Disease) is palliated by {v} (Compound)",
"Metamfetamine"
]
]
] |
Bupropion may lead to a major life threatening interaction when taken with Benzphetamine and Benzphetamine (Compound) resembles Metamfetamine (Compound)
Bupropion may lead to a major life threatening interaction when taken with Dextroamphetamine and Dextroamphetamine (Compound) resembles Metamfetamine (Compound)
Bupropion may lead to a major life threatening interaction when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine
Bupropion may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Metamfetamine
Bupropion may lead to a major life threatening interaction when taken with Phenelzine and Phenelzine (Compound) resembles Metamfetamine (Compound)
Bupropion may lead to a major life threatening interaction when taken with Lisdexamfetamine and Lisdexamfetamine (Compound) resembles Metamfetamine (Compound)
Bupropion (Compound) treats obesity (Disease) and obesity (Disease) is treated by Metamfetamine (Compound)
Bupropion (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Metamfetamine (Compound)
Bupropion (Compound) palliates attention deficit hyperactivity disorder (Disease) and attention deficit hyperactivity disorder (Disease) is palliated by Metamfetamine (Compound)
|
DB00405
|
DB11601
| 128
| 1,270
|
[
"DDInter517",
"DDInter1889"
] |
Dexbrompheniramine
|
Tuberculin purified protein derivative
|
Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.
|
Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines.
|
Moderate
| 1
|
[
[
[
128,
24,
1270
]
],
[
[
128,
24,
13
],
[
13,
24,
1270
]
],
[
[
128,
63,
1242
],
[
1242,
24,
1270
]
],
[
[
128,
24,
13
],
[
13,
63,
1242
],
[
1242,
24,
1270
]
],
[
[
128,
63,
1242
],
[
1242,
24,
13
],
[
13,
24,
1270
]
],
[
[
128,
24,
1053
],
[
1053,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
128,
24,
770
],
[
770,
64,
550
],
[
550,
24,
1270
]
],
[
[
128,
63,
701
],
[
701,
35,
1242
],
[
1242,
24,
1270
]
],
[
[
128,
63,
1242
],
[
1242,
40,
1413
],
[
1413,
24,
1270
]
],
[
[
128,
63,
695
],
[
695,
25,
350
],
[
350,
24,
1270
]
]
] |
[
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab"
],
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} (Compound) resembles {v} (Compound)",
"Fexofenadine"
],
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
]
] |
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Trastuzumab and Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine (Compound) resembles Cetirizine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine (Compound) resembles Fexofenadine (Compound) and Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
|
DB00015
|
DB00749
| 582
| 59
|
[
"DDInter1585",
"DDInter699"
] |
Reteplase
|
Etodolac
|
Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).
|
Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.
|
Moderate
| 1
|
[
[
[
582,
24,
59
]
],
[
[
582,
24,
1018
],
[
1018,
24,
59
]
],
[
[
582,
24,
1039
],
[
1039,
63,
59
]
],
[
[
582,
64,
1578
],
[
1578,
24,
59
]
],
[
[
582,
25,
1046
],
[
1046,
63,
59
]
],
[
[
582,
25,
1432
],
[
1432,
24,
59
]
],
[
[
582,
25,
235
],
[
235,
64,
59
]
],
[
[
582,
25,
1172
],
[
1172,
25,
59
]
],
[
[
582,
24,
1018
],
[
1018,
6,
6017
],
[
6017,
45,
59
]
],
[
[
582,
64,
1578
],
[
1578,
25,
25
],
[
25,
24,
59
]
]
] |
[
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etodolac"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etodolac"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etodolac"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etodolac"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
],
[
"Caplacizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etodolac"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abciximab"
],
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etodolac"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etodolac"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
],
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etodolac"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Etodolac"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anistreplase"
],
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etodolac"
]
]
] |
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Etodolac
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Etodolac
Reteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Etodolac
Reteplase may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Etodolac
Reteplase may lead to a major life threatening interaction when taken with Abciximab and Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Etodolac
Reteplase may lead to a major life threatening interaction when taken with Desirudin and Desirudin may lead to a major life threatening interaction when taken with Etodolac
Reteplase may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Etodolac
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Etodolac (Compound)
Reteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Etodolac
|
DB01045
|
DB12500
| 463
| 283
|
[
"DDInter1590",
"DDInter714"
] |
Rifampicin
|
Fedratinib
|
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
|
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019.
|
Major
| 2
|
[
[
[
463,
25,
283
]
],
[
[
463,
25,
466
],
[
466,
62,
283
]
],
[
[
463,
25,
351
],
[
351,
23,
283
]
],
[
[
463,
64,
1419
],
[
1419,
24,
283
]
],
[
[
463,
24,
761
],
[
761,
24,
283
]
],
[
[
463,
25,
436
],
[
436,
24,
283
]
],
[
[
463,
25,
676
],
[
676,
63,
283
]
],
[
[
463,
63,
147
],
[
147,
24,
283
]
],
[
[
463,
62,
1101
],
[
1101,
24,
283
]
],
[
[
463,
23,
1264
],
[
1264,
24,
283
]
]
] |
[
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Artemether"
],
[
"Artemether",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Rifampicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Rifampicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
]
] |
Rifampicin may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Rifampicin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Rifampicin may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Rifampicin may lead to a major life threatening interaction when taken with Artemether and Artemether may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Rifampicin may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Rifampicin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Rifampicin may cause a minor interaction that can limit clinical effects when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
|
DB00443
|
DB10795
| 251
| 221
|
[
"DDInter195",
"DDInter1486"
] |
Betamethasone
|
Poliovirus type 1 antigen (formaldehyde inactivated)
|
Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity.
|
Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a continuous line of monkey kidney cells.
|
Moderate
| 1
|
[
[
[
251,
24,
221
]
],
[
[
251,
64,
581
],
[
581,
24,
221
]
],
[
[
251,
63,
599
],
[
599,
24,
221
]
],
[
[
251,
1,
1486
],
[
1486,
24,
221
]
],
[
[
251,
24,
384
],
[
384,
24,
221
]
],
[
[
251,
25,
1510
],
[
1510,
24,
221
]
],
[
[
251,
24,
351
],
[
351,
63,
221
]
],
[
[
251,
25,
676
],
[
676,
63,
221
]
],
[
[
251,
40,
167
],
[
167,
24,
221
]
],
[
[
251,
64,
581
],
[
581,
25,
36
],
[
36,
24,
221
]
]
] |
[
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
]
] |
Betamethasone may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Betamethasone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Betamethasone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Betamethasone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Betamethasone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Betamethasone may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
|
DB01110
|
DB09389
| 86
| 517
|
[
"DDInter1209",
"DDInter1315"
] |
Miconazole
|
Norgestrel
|
Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-based products are available.[L14021, L14024, L14027, L14033, L14396] Miconazole is thought to act primarily through the inhibition of fungal CYP450 14α-lanosterol demethylase activity.[A203636, A203639] Miconazole was first synthesized in 1969 and first granted FDA approval on January 8, 1974, for sale by INSIGHT Pharmaceuticals as a topical cream.[A214523, L14021] It is currently available as a variety of prescription and over the counter products. Despite having been in clinical use for an extended period, resistance to m
|
Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active.
|
Moderate
| 1
|
[
[
[
86,
24,
517
]
],
[
[
86,
24,
159
],
[
159,
63,
517
]
],
[
[
86,
24,
129
],
[
129,
24,
517
]
],
[
[
86,
63,
600
],
[
600,
24,
517
]
],
[
[
86,
25,
1411
],
[
1411,
24,
517
]
],
[
[
86,
64,
245
],
[
245,
24,
517
]
],
[
[
86,
24,
1476
],
[
1476,
64,
517
]
],
[
[
86,
62,
1101
],
[
1101,
25,
517
]
],
[
[
86,
24,
159
],
[
159,
63,
1130
],
[
1130,
23,
517
]
],
[
[
86,
24,
129
],
[
129,
25,
159
],
[
159,
63,
517
]
]
] |
[
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Miconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Miconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norgestrel"
]
],
[
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norgestrel"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
],
[
"Pioglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norgestrel"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
]
] |
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Miconazole may lead to a major life threatening interaction when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Miconazole may lead to a major life threatening interaction when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may lead to a major life threatening interaction when taken with Norgestrel
Miconazole may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Norgestrel
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
|
DB00312
|
DB00341
| 1,023
| 1,242
|
[
"DDInter1423",
"DDInter343"
] |
Pentobarbital
|
Cetirizine
|
A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
|
Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms , . One of the most common uses for this drug is for a condition called _allergic rhinitis_. The prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms. Allergic rhinitis is associated with multiple missed or unproductive days at work and school, problems with sleep, and other difficulties with day to day activities for many individuals . Furthermore, some antihistamine agents that are used to treat this condition cause undesirable, sedating effects . Cetirizine is one of the first second-generation H1 antihistamines (SGAHs) formulated to selectively inhibit the H1 receptor without sedating effects .
|
Moderate
| 1
|
[
[
[
1023,
24,
1242
]
],
[
[
1023,
24,
537
],
[
537,
63,
1242
]
],
[
[
1023,
21,
29027
],
[
29027,
60,
1242
]
],
[
[
1023,
63,
1031
],
[
1031,
23,
1242
]
],
[
[
1023,
64,
475
],
[
475,
24,
1242
]
],
[
[
1023,
1,
288
],
[
288,
24,
1242
]
],
[
[
1023,
63,
1648
],
[
1648,
24,
1242
]
],
[
[
1023,
1,
697
],
[
697,
63,
1242
]
],
[
[
1023,
63,
701
],
[
701,
35,
1242
]
],
[
[
1023,
24,
537
],
[
537,
40,
11304
],
[
11304,
1,
1242
]
]
] |
[
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Pentobarbital",
"{u} (Compound) causes {v} (Side Effect)",
"Ataxia"
],
[
"Ataxia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cetirizine"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cetirizine"
]
],
[
[
"Pentobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Pentobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Butalbital"
],
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Pentobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Ifenprodil"
],
[
"Ifenprodil",
"{u} (Compound) resembles {v} (Compound)",
"Cetirizine"
]
]
] |
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Pentobarbital (Compound) causes Ataxia (Side Effect) and Ataxia (Side Effect) is caused by Cetirizine (Compound)
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Cetirizine
Pentobarbital may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Pentobarbital (Compound) resembles Butalbital (Compound) and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Pentobarbital (Compound) resembles Phenobarbital (Compound) and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine (Compound) resembles Cetirizine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Ifenprodil (Compound) and Ifenprodil (Compound) resembles Cetirizine (Compound)
|
DB01097
|
DB01157
| 1,377
| 304
|
[
"DDInter1033",
"DDInter1875"
] |
Leflunomide
|
Trimetrexate
|
Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
|
A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
|
Major
| 2
|
[
[
[
1377,
25,
304
]
],
[
[
1377,
21,
28703
],
[
28703,
60,
304
]
],
[
[
1377,
64,
600
],
[
600,
23,
304
]
],
[
[
1377,
64,
58
],
[
58,
24,
304
]
],
[
[
1377,
24,
1270
],
[
1270,
63,
304
]
],
[
[
1377,
25,
1613
],
[
1613,
63,
304
]
],
[
[
1377,
63,
563
],
[
563,
24,
304
]
],
[
[
1377,
25,
1070
],
[
1070,
64,
304
]
],
[
[
1377,
64,
695
],
[
695,
25,
304
]
],
[
[
1377,
21,
28703
],
[
28703,
60,
1548
],
[
1548,
40,
304
]
]
] |
[
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trimetrexate"
]
],
[
[
"Leflunomide",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Trimetrexate"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trimetrexate"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimetrexate"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
],
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimetrexate"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimetrexate"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimetrexate"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
],
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trimetrexate"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trimetrexate"
]
],
[
[
"Leflunomide",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Trimethoprim"
],
[
"Trimethoprim",
"{u} (Compound) resembles {v} (Compound)",
"Trimetrexate"
]
]
] |
Leflunomide (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Trimetrexate (Compound)
Leflunomide may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Trimetrexate
Leflunomide may lead to a major life threatening interaction when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Trimetrexate
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Trimetrexate
Leflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Trimetrexate
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Trimetrexate
Leflunomide may lead to a major life threatening interaction when taken with Mipomersen and Mipomersen may lead to a major life threatening interaction when taken with Trimetrexate
Leflunomide may lead to a major life threatening interaction when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Trimetrexate
Leflunomide (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Trimethoprim (Compound) and Trimethoprim (Compound) resembles Trimetrexate (Compound)
|
DB00675
|
DB09075
| 888
| 498
|
[
"DDInter1744",
"DDInter621"
] |
Tamoxifen
|
Edoxaban
|
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977.
|
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy.
|
Major
| 2
|
[
[
[
888,
25,
498
]
],
[
[
888,
64,
109
],
[
109,
24,
498
]
],
[
[
888,
24,
1237
],
[
1237,
24,
498
]
],
[
[
888,
24,
1017
],
[
1017,
63,
498
]
],
[
[
888,
25,
1039
],
[
1039,
24,
498
]
],
[
[
888,
63,
1100
],
[
1100,
24,
498
]
],
[
[
888,
25,
1456
],
[
1456,
63,
498
]
],
[
[
888,
24,
1213
],
[
1213,
25,
498
]
],
[
[
888,
25,
762
],
[
762,
25,
498
]
],
[
[
888,
25,
283
],
[
283,
64,
498
]
]
] |
[
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bepridil"
],
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
]
] |
Tamoxifen may lead to a major life threatening interaction when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Tamoxifen may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Tamoxifen may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Edoxaban
Tamoxifen may lead to a major life threatening interaction when taken with Bepridil and Bepridil may lead to a major life threatening interaction when taken with Edoxaban
Tamoxifen may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Edoxaban
|
DB00307
|
DB00776
| 1,101
| 1,335
|
[
"DDInter202",
"DDInter1360"
] |
Bexarotene
|
Oxcarbazepine
|
Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.
|
Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate in the blood - a pro-drug of the more active (S)-enantiomer is also marketed as a separate anti-epileptic under the name [eslicarbazepine]. Compared to other anti-epileptic drugs, which are generally metabolized via the cytochrome P450 system, oxcarbazepine has a reduced propensity for involvement in drug-drug interactions owing to its primarily reductive metabolism.
|
Minor
| 0
|
[
[
[
1101,
23,
1335
]
],
[
[
1101,
23,
1236
],
[
1236,
1,
1335
]
],
[
[
1101,
24,
307
],
[
307,
1,
1335
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
1335
]
],
[
[
1101,
21,
28789
],
[
28789,
60,
1335
]
],
[
[
1101,
62,
168
],
[
168,
23,
1335
]
],
[
[
1101,
25,
971
],
[
971,
63,
1335
]
],
[
[
1101,
24,
1547
],
[
1547,
63,
1335
]
],
[
[
1101,
23,
1419
],
[
1419,
24,
1335
]
],
[
[
1101,
24,
134
],
[
134,
24,
1335
]
]
] |
[
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} (Compound) resembles {v} (Compound)",
"Oxcarbazepine"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} (Compound) resembles {v} (Compound)",
"Oxcarbazepine"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Oxcarbazepine"
]
],
[
[
"Bexarotene",
"{u} (Compound) causes {v} (Side Effect)",
"Loss of consciousness"
],
[
"Loss of consciousness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Oxcarbazepine"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exemestane"
],
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
]
] |
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Carbamazepine and Carbamazepine (Compound) resembles Oxcarbazepine (Compound)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil (Compound) resembles Oxcarbazepine (Compound)
Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Oxcarbazepine (Compound)
Bexarotene (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Oxcarbazepine (Compound)
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Oxcarbazepine
Bexarotene may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Exemestane and Exemestane may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine
|
DB00023
|
DB00519
| 305
| 1,638
|
[
"DDInter127",
"DDInter1843"
] |
Asparaginase Escherichia coli
|
Trandolapril
|
Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997]. L-asparaginase of _E. coli_ is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections. Therapeutic L-asparaginase from _E. coli_ works by depleting the levels
|
Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
|
Moderate
| 1
|
[
[
[
305,
24,
1638
]
],
[
[
305,
24,
954
],
[
954,
40,
1638
]
],
[
[
305,
24,
170
],
[
170,
63,
1638
]
],
[
[
305,
24,
590
],
[
590,
24,
1638
]
],
[
[
305,
25,
1377
],
[
1377,
64,
1638
]
],
[
[
305,
24,
1144
],
[
1144,
74,
1638
]
],
[
[
305,
24,
954
],
[
954,
40,
1058
],
[
1058,
40,
1638
]
],
[
[
305,
24,
1058
],
[
1058,
1,
954
],
[
954,
40,
1638
]
],
[
[
305,
24,
170
],
[
170,
63,
1058
],
[
1058,
40,
1638
]
],
[
[
305,
24,
175
],
[
175,
24,
954
],
[
954,
40,
1638
]
]
] |
[
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
"Quinapril",
"{u} (Compound) resembles {v} (Compound)",
"Trandolapril"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trandolapril"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
"Quinapril",
"{u} (Compound) resembles {v} (Compound)",
"Moexipril"
],
[
"Moexipril",
"{u} (Compound) resembles {v} (Compound)",
"Trandolapril"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moexipril"
],
[
"Moexipril",
"{u} (Compound) resembles {v} (Compound)",
"Quinapril"
],
[
"Quinapril",
"{u} (Compound) resembles {v} (Compound)",
"Trandolapril"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moexipril"
],
[
"Moexipril",
"{u} (Compound) resembles {v} (Compound)",
"Trandolapril"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
"Quinapril",
"{u} (Compound) resembles {v} (Compound)",
"Trandolapril"
]
]
] |
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Trandolapril (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Trandolapril
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide (Compound) resembles Trandolapril (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Moexipril (Compound) and Moexipril (Compound) resembles Trandolapril (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Moexipril and Moexipril (Compound) resembles Quinapril (Compound) and Quinapril (Compound) resembles Trandolapril (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Moexipril and Moexipril (Compound) resembles Trandolapril (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Trandolapril (Compound)
|
DB00690
|
DB09065
| 1,216
| 760
|
[
"DDInter762",
"DDInter424"
] |
Flurazepam
|
Cobicistat
|
A benzodiazepine derivative used mainly as a hypnotic.
|
Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile.
|
Moderate
| 1
|
[
[
[
1216,
24,
760
]
],
[
[
1216,
40,
523
],
[
523,
24,
760
]
],
[
[
1216,
24,
609
],
[
609,
24,
760
]
],
[
[
1216,
63,
1419
],
[
1419,
24,
760
]
],
[
[
1216,
24,
1619
],
[
1619,
63,
760
]
],
[
[
1216,
24,
1017
],
[
1017,
64,
760
]
],
[
[
1216,
24,
129
],
[
129,
25,
760
]
],
[
[
1216,
40,
1382
],
[
1382,
25,
760
]
],
[
[
1216,
40,
523
],
[
523,
63,
1101
],
[
1101,
23,
760
]
],
[
[
1216,
24,
609
],
[
609,
62,
479
],
[
479,
23,
760
]
]
] |
[
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Alprazolam"
],
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Midazolam"
],
[
"Midazolam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Alprazolam"
],
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
]
] |
Flurazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Cobicistat
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Cobicistat
Flurazepam (Compound) resembles Midazolam (Compound) and Midazolam may lead to a major life threatening interaction when taken with Cobicistat
Flurazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
|
DB01218
|
DB11901
| 1,493
| 913
|
[
"DDInter852",
"DDInter107"
] |
Halofantrine
|
Apalutamide
|
Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity.
|
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors . In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or . Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines . Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which is the second-most common cause of cancer-related deaths in American males . Castration-resistant prostate cancer is often incurable, which poses significant clinical challenges for patients. Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis . Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death . In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment . In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo . Apalutamide displayed good tolerability and safety profile in clinical studies. Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant). It is available as oral tablets. Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer .
|
Major
| 2
|
[
[
[
1493,
25,
913
]
],
[
[
1493,
62,
112
],
[
112,
23,
913
]
],
[
[
1493,
64,
600
],
[
600,
24,
913
]
],
[
[
1493,
24,
28
],
[
28,
24,
913
]
],
[
[
1493,
25,
1237
],
[
1237,
24,
913
]
],
[
[
1493,
25,
877
],
[
877,
63,
913
]
],
[
[
1493,
62,
211
],
[
211,
24,
913
]
],
[
[
1493,
63,
455
],
[
455,
24,
913
]
],
[
[
1493,
24,
1032
],
[
1032,
63,
913
]
],
[
[
1493,
25,
1623
],
[
1623,
25,
913
]
]
] |
[
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Halofantrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
],
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Halofantrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Halofantrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Halofantrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Halofantrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
],
[
"Levosalbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isavuconazonium"
],
[
"Isavuconazonium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
]
] |
Halofantrine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Halofantrine may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Halofantrine may lead to a major life threatening interaction when taken with Clomipramine and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Halofantrine may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Halofantrine may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Halofantrine may lead to a major life threatening interaction when taken with Isavuconazonium and Isavuconazonium may lead to a major life threatening interaction when taken with Apalutamide
|
DB06209
|
DB06822
| 256
| 802
|
[
"DDInter1508",
"DDInter1812"
] |
Prasugrel
|
Tinzaparin
|
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.
|
Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
|
Major
| 2
|
[
[
[
256,
25,
802
]
],
[
[
256,
23,
944
],
[
944,
62,
802
]
],
[
[
256,
63,
222
],
[
222,
24,
802
]
],
[
[
256,
24,
1427
],
[
1427,
63,
802
]
],
[
[
256,
24,
643
],
[
643,
24,
802
]
],
[
[
256,
64,
1432
],
[
1432,
25,
802
]
],
[
[
256,
75,
1347
],
[
1347,
25,
802
]
],
[
[
256,
25,
1409
],
[
1409,
25,
802
]
],
[
[
256,
25,
405
],
[
405,
64,
802
]
],
[
[
256,
63,
1479
],
[
1479,
25,
802
]
]
] |
[
[
[
"Prasugrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Prasugrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tinzaparin"
]
],
[
[
"Prasugrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Prasugrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
],
[
"Vortioxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Prasugrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Prasugrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abciximab"
],
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Prasugrel",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Prasugrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Prasugrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Prasugrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
]
] |
Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Tinzaparin
Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Prasugrel may lead to a major life threatening interaction when taken with Abciximab and Abciximab may lead to a major life threatening interaction when taken with Tinzaparin
Prasugrel (Compound) resembles Clopidogrel (Compound) and Prasugrel may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Tinzaparin
Prasugrel may lead to a major life threatening interaction when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Tinzaparin
Prasugrel may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may lead to a major life threatening interaction when taken with Tinzaparin
Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Tinzaparin
|
DB00213
|
DB00705
| 837
| 441
|
[
"DDInter1388",
"DDInter496"
] |
Pantoprazole
|
Delavirdine
|
Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including [amoxicillin], [clarithromycin], and [metronidazole], for example. Its efficacy is considered similar to other medications within the PPI class including [omeprazole], [esomeprazole], [lansoprazole], [dexlansoprazole], and [rabeprazole]. Pantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups
|
A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
|
Moderate
| 1
|
[
[
[
837,
24,
441
]
],
[
[
837,
6,
10215
],
[
10215,
45,
441
]
],
[
[
837,
21,
28709
],
[
28709,
60,
441
]
],
[
[
837,
1,
379
],
[
379,
63,
441
]
],
[
[
837,
24,
126
],
[
126,
24,
441
]
],
[
[
837,
24,
1347
],
[
1347,
63,
441
]
],
[
[
837,
25,
1195
],
[
1195,
24,
441
]
],
[
[
837,
62,
168
],
[
168,
24,
441
]
],
[
[
837,
63,
600
],
[
600,
24,
441
]
],
[
[
837,
1,
1215
],
[
1215,
24,
441
]
]
] |
[
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Pantoprazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Delavirdine"
]
],
[
[
"Pantoprazole",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Delavirdine"
]
],
[
[
"Pantoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Pantoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erlotinib"
],
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Pantoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Pantoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
]
] |
Pantoprazole (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Delavirdine (Compound)
Pantoprazole (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Delavirdine (Compound)
Pantoprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Pantoprazole may lead to a major life threatening interaction when taken with Erlotinib and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Pantoprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
|
DB00342
|
DB00468
| 1,181
| 1,424
|
[
"DDInter1770",
"DDInter1557"
] |
Terfenadine
|
Quinine
|
In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.
|
An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood.
|
Major
| 2
|
[
[
[
1181,
25,
1424
]
],
[
[
1181,
24,
307
],
[
307,
62,
1424
]
],
[
[
1181,
23,
1247
],
[
1247,
62,
1424
]
],
[
[
1181,
64,
529
],
[
529,
23,
1424
]
],
[
[
1181,
25,
752
],
[
752,
62,
1424
]
],
[
[
1181,
24,
1612
],
[
1612,
63,
1424
]
],
[
[
1181,
25,
1080
],
[
1080,
63,
1424
]
],
[
[
1181,
63,
534
],
[
534,
24,
1424
]
],
[
[
1181,
24,
1251
],
[
1251,
24,
1424
]
],
[
[
1181,
64,
798
],
[
798,
24,
1424
]
]
] |
[
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinine"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinine"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinine"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinine"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conivaptan"
],
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
]
]
] |
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Quinine
Terfenadine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Quinine
Terfenadine may lead to a major life threatening interaction when taken with Fluvoxamine and Fluvoxamine may cause a minor interaction that can limit clinical effects when taken with Quinine
Terfenadine may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Quinine
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Terfenadine may lead to a major life threatening interaction when taken with Conivaptan and Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Mirtazapine and Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Terfenadine may lead to a major life threatening interaction when taken with Nelfinavir and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Quinine
|
DB11691
|
DB12035
| 1,499
| 943
|
[
"DDInter1258",
"DDInter1641"
] |
Naldemedine
|
Sarecycline
|
Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation.
|
Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris [A39993, A39994] the US Food and Drug Administration approved Barcelona based Almirall, S.A.'s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age and older . Seysara (sarecycline) was originally part of Allergan's US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the dermatology-focused pharmaceutical company's presence in the United States . Acne vulgaris itself is a common chronic skin condition associated with the blockage and/or inflammation of hair follicles and their accompanying sebaceous glands . The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well . Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental scarring resulting from cases of severe acne . Subsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because it exhibits the necessary antibacterial activity against relevant pathogens that cause acne vulgaris but also possesses a low propensity for resistance development in such pathogens and a narrower, more specific spectrum of antibacterial activity, resulting in fewer off-target antibacterial effects on endogenous intestinal flora and consequently fewer resultant adverse effects associated with diarrhea, fungal overgrowth, etc.
|
Moderate
| 1
|
[
[
[
1499,
24,
943
]
],
[
[
1499,
63,
1135
],
[
1135,
23,
943
]
],
[
[
1499,
63,
1456
],
[
1456,
24,
943
]
],
[
[
1499,
24,
1619
],
[
1619,
63,
943
]
],
[
[
1499,
63,
1135
],
[
1135,
23,
1456
],
[
1456,
24,
943
]
],
[
[
1499,
63,
1456
],
[
1456,
62,
1135
],
[
1135,
23,
943
]
],
[
[
1499,
63,
1670
],
[
1670,
23,
1135
],
[
1135,
23,
943
]
],
[
[
1499,
24,
1619
],
[
1619,
62,
1135
],
[
1135,
23,
943
]
],
[
[
1499,
63,
384
],
[
384,
64,
1135
],
[
1135,
23,
943
]
],
[
[
1499,
63,
1419
],
[
1419,
25,
1135
],
[
1135,
23,
943
]
]
] |
[
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sarecycline"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sarecycline"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sarecycline"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sarecycline"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sarecycline"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sarecycline"
]
]
] |
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Sarecycline
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Sarecycline
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Sarecycline
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Sarecycline
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Sarecycline
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Sarecycline
|
DB00215
|
DB00397
| 1,230
| 1,466
|
[
"DDInter388",
"DDInter1458"
] |
Citalopram
|
Phenylpropanolamine
|
Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake inhibition.[A261316,A14720] Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors. Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older.
|
Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.
|
Major
| 2
|
[
[
[
1230,
25,
1466
]
],
[
[
1230,
64,
73
],
[
73,
25,
1466
]
],
[
[
1230,
6,
7390
],
[
7390,
45,
1466
]
],
[
[
1230,
21,
29027
],
[
29027,
60,
1466
]
],
[
[
1230,
24,
1662
],
[
1662,
63,
1466
]
],
[
[
1230,
24,
999
],
[
999,
24,
1466
]
],
[
[
1230,
25,
1674
],
[
1674,
63,
1466
]
],
[
[
1230,
63,
1179
],
[
1179,
24,
1466
]
],
[
[
1230,
25,
593
],
[
593,
64,
1466
]
],
[
[
1230,
1,
318
],
[
318,
64,
1466
]
]
] |
[
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylpropanolamine"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylpropanolamine"
]
],
[
[
"Citalopram",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
],
[
"SLC6A2",
"{u} (Gene) is bound by {v} (Compound)",
"Phenylpropanolamine"
]
],
[
[
"Citalopram",
"{u} (Compound) causes {v} (Side Effect)",
"Ataxia"
],
[
"Ataxia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Phenylpropanolamine"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylpropanolamine"
]
],
[
[
"Citalopram",
"{u} (Compound) resembles {v} (Compound)",
"Escitalopram"
],
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylpropanolamine"
]
]
] |
Citalopram may lead to a major life threatening interaction when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Phenylpropanolamine
Citalopram (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Phenylpropanolamine (Compound)
Citalopram (Compound) causes Ataxia (Side Effect) and Ataxia (Side Effect) is caused by Phenylpropanolamine (Compound)
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine
Citalopram may lead to a major life threatening interaction when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine
Citalopram may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Phenylpropanolamine
Citalopram (Compound) resembles Escitalopram (Compound) and Es
|
DB00331
|
DB11255
| 1,645
| 1,371
|
[
"DDInter1164",
"DDInter374"
] |
Metformin
|
Chromium picolinate
|
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes. Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
|
Chromium picolinate has a chemical formula CrPic3 and reddish-pink color. It is a coordination complex consisting of chromium(III) and picolinic acid. Chromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss. Chromium ions are shown to regulate insulin by promoting glucose utilization and increasing the sensitivity of the insulin receptor .
|
Moderate
| 1
|
[
[
[
1645,
24,
1371
]
],
[
[
1645,
63,
245
],
[
245,
24,
1371
]
],
[
[
1645,
24,
473
],
[
473,
24,
1371
]
],
[
[
1645,
62,
1647
],
[
1647,
24,
1371
]
],
[
[
1645,
63,
245
],
[
245,
24,
5
],
[
5,
24,
1371
]
],
[
[
1645,
24,
473
],
[
473,
24,
5
],
[
5,
24,
1371
]
],
[
[
1645,
24,
1296
],
[
1296,
63,
245
],
[
245,
24,
1371
]
],
[
[
1645,
24,
959
],
[
959,
1,
245
],
[
245,
24,
1371
]
],
[
[
1645,
62,
1647
],
[
1647,
24,
1021
],
[
1021,
24,
1371
]
],
[
[
1645,
5,
11640
],
[
11640,
44,
245
],
[
245,
24,
1371
]
]
] |
[
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Metformin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
],
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
],
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Metformin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
],
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Metformin",
"{u} (Compound) treats {v} (Disease)",
"type 2 diabetes mellitus"
],
[
"type 2 diabetes mellitus",
"{u} (Disease) is treated by {v} (Compound)",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
]
] |
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Metformin may cause a minor interaction that can limit clinical effects when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Metformin may cause a minor interaction that can limit clinical effects when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Metformin (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
|
DB00927
|
DB00978
| 1,559
| 739
|
[
"DDInter712",
"DDInter1084"
] |
Famotidine
|
Lomefloxacin
|
Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than [cimetidine] and eight times more potent than [ranitidine] on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.
|
Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.
|
Moderate
| 1
|
[
[
[
1559,
24,
739
]
],
[
[
1559,
24,
945
],
[
945,
40,
739
]
],
[
[
1559,
63,
1176
],
[
1176,
1,
739
]
],
[
[
1559,
62,
1467
],
[
1467,
40,
739
]
],
[
[
1559,
21,
28921
],
[
28921,
60,
739
]
],
[
[
1559,
63,
51
],
[
51,
23,
739
]
],
[
[
1559,
24,
77
],
[
77,
62,
739
]
],
[
[
1559,
62,
112
],
[
112,
23,
739
]
],
[
[
1559,
24,
124
],
[
124,
63,
739
]
],
[
[
1559,
63,
485
],
[
485,
24,
739
]
]
] |
[
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Lomefloxacin"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Lomefloxacin"
]
],
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enoxacin"
],
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Lomefloxacin"
]
],
[
[
"Famotidine",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lomefloxacin"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
]
]
] |
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Lomefloxacin (Compound)
Famotidine may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Lomefloxacin (Compound)
Famotidine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Lomefloxacin (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin
Famotidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin
|
DB06448
|
DB09074
| 171
| 1,362
|
[
"DDInter1087",
"DDInter1327"
] |
Lonafarnib
|
Olaparib
|
Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.[A224379, A224394] Lonafarnib is a farnesyl transferase (FTase) inhibitor (FT
|
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016.
|
Major
| 2
|
[
[
[
171,
25,
1362
]
],
[
[
171,
63,
896
],
[
896,
24,
1362
]
],
[
[
171,
25,
1478
],
[
1478,
24,
1362
]
],
[
[
171,
64,
467
],
[
467,
24,
1362
]
],
[
[
171,
25,
1619
],
[
1619,
63,
1362
]
],
[
[
171,
24,
98
],
[
98,
63,
1362
]
],
[
[
171,
24,
310
],
[
310,
24,
1362
]
],
[
[
171,
25,
760
],
[
760,
25,
1362
]
],
[
[
171,
25,
676
],
[
676,
64,
1362
]
],
[
[
171,
64,
1220
],
[
1220,
25,
1362
]
]
] |
[
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
]
] |
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Lonafarnib may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Lonafarnib may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Lonafarnib may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Lonafarnib may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Olaparib
Lonafarnib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Olaparib
Lonafarnib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Olaparib
|
DB00717
|
DB14724
| 1,197
| 48
|
[
"DDInter1312",
"DDInter634"
] |
Norethisterone
|
Emapalumab
|
Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [norethynodrel] and [lynestrenol]. Norethisterone mimics the actions of endogenous [progesterone], albeit with a greater potency, and is used on its own or in combination with estrogen derivatives in a variety of applications including contraception and hormone replacement therapy.[L9527,L10301,L10304,L10307] First derived in 1951 in Mexico City, norethisterone was originally intended for use as a remedy for irregular menstruation and endometriosis, and was not marketed for use as an oral contraceptive until 1962.
|
Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.[A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough therapy. As well, emapalumab was given the status of PRIME by the EMA.
|
Moderate
| 1
|
[
[
[
1197,
24,
48
]
],
[
[
1197,
40,
890
],
[
890,
24,
48
]
],
[
[
1197,
1,
1336
],
[
1336,
24,
48
]
],
[
[
1197,
63,
1031
],
[
1031,
24,
48
]
],
[
[
1197,
40,
890
],
[
890,
63,
126
],
[
126,
24,
48
]
],
[
[
1197,
1,
1336
],
[
1336,
40,
890
],
[
890,
24,
48
]
],
[
[
1197,
63,
1031
],
[
1031,
63,
362
],
[
362,
24,
48
]
],
[
[
1197,
6,
4973
],
[
4973,
45,
1463
],
[
1463,
24,
48
]
],
[
[
1197,
40,
890
],
[
890,
1,
1336
],
[
1336,
24,
48
]
],
[
[
1197,
1,
1336
],
[
1336,
63,
1031
],
[
1031,
24,
48
]
]
] |
[
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
],
[
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
],
[
"Mestranol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
],
[
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Etonogestrel"
],
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
],
[
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
],
[
"Mestranol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
],
[
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Etonogestrel"
],
[
"Etonogestrel",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
],
[
"Mestranol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
],
[
[
"Norethisterone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Lovastatin"
],
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
],
[
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
],
[
"Mestranol",
"{u} (Compound) resembles {v} (Compound)",
"Etonogestrel"
],
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
],
[
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Etonogestrel"
],
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
]
] |
Norethisterone (Compound) resembles Mestranol (Compound) and Mestranol may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
Norethisterone (Compound) resembles Etonogestrel (Compound) and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
Norethisterone (Compound) resembles Mestranol (Compound) and Mestranol may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
Norethisterone (Compound) resembles Etonogestrel (Compound) and Etonogestrel (Compound) resembles Mestranol (Compound) and Mestranol may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
Norethisterone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lovastatin (Compound) and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
Norethisterone (Compound) resembles Mestranol (Compound) and Mestranol (Compound) resembles Etonogestrel (Compound) and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
Norethisterone (Compound) resembles Etonogestrel (Compound) and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
|
DB04845
|
DB08873
| 309
| 74
|
[
"DDInter1001",
"DDInter221"
] |
Ixabepilone
|
Boceprevir
|
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation.
|
Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients . Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B [FDA Label]. The barrier for develoment of resistance to NS3/4A inhibitors is lower than that of NS5B inhibitors, another class of DAAs . Subtitutions at amino acid positions 155, 156, or 168 are known to confer resistance. The substitutions of the enzyme's catalytic triad consisting of H58, D82, and S139 are also likely to alter the affinity of the drug for NS3/4A or the activity of the enzyme itself. Despite this disadvantage Boceprevir is still effective against HCV when paired with , , and . In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) do not reccomend Boceprevir in combination with , , and as first line therapy for Hepatitis C . Boceprevir, , , and are used with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality . Boceprevir is available as a fixed dose product (tradename Victrelis) used for the treatment of chronic Hepatitis C. Approved in May 2011 by the FDA, Victrelis is indicated for the treatment of HCV genotype 1 in combination with , , and [FDA Label]. Victrelis is no longer widely used as interferon-free therapies have been developed.
|
Moderate
| 1
|
[
[
[
309,
24,
74
]
],
[
[
309,
6,
8374
],
[
8374,
45,
74
]
],
[
[
309,
21,
28821
],
[
28821,
60,
74
]
],
[
[
309,
24,
310
],
[
310,
24,
74
]
],
[
[
309,
63,
86
],
[
86,
24,
74
]
],
[
[
309,
24,
710
],
[
710,
63,
74
]
],
[
[
309,
24,
971
],
[
971,
64,
74
]
],
[
[
309,
25,
676
],
[
676,
64,
74
]
],
[
[
309,
63,
392
],
[
392,
25,
74
]
],
[
[
309,
24,
1593
],
[
1593,
25,
74
]
]
] |
[
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Ixabepilone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Boceprevir"
]
],
[
[
"Ixabepilone",
"{u} (Compound) causes {v} (Side Effect)",
"Sepsis"
],
[
"Sepsis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Boceprevir"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
],
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
],
[
[
"Ixabepilone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
]
] |
Ixabepilone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Boceprevir (Compound)
Ixabepilone (Compound) causes Sepsis (Side Effect) and Sepsis (Side Effect) is caused by Boceprevir (Compound)
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may lead to a major life threatening interaction when taken with Boceprevir
Ixabepilone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Boceprevir
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Boceprevir
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Boceprevir
|
DB06595
|
DB09082
| 1,491
| 659
|
[
"DDInter1214",
"DDInter1934"
] |
Midostaurin
|
Vilanterol
|
Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors. It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
|
Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456]
|
Moderate
| 1
|
[
[
[
1491,
24,
659
]
],
[
[
1491,
63,
1220
],
[
1220,
23,
659
]
],
[
[
1491,
63,
1570
],
[
1570,
24,
659
]
],
[
[
1491,
24,
1296
],
[
1296,
63,
659
]
],
[
[
1491,
25,
1155
],
[
1155,
63,
659
]
],
[
[
1491,
64,
1069
],
[
1069,
24,
659
]
],
[
[
1491,
24,
1450
],
[
1450,
24,
659
]
],
[
[
1491,
25,
129
],
[
129,
24,
659
]
],
[
[
1491,
25,
877
],
[
877,
64,
659
]
],
[
[
1491,
64,
17
],
[
17,
25,
659
]
]
] |
[
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
],
[
"Tucatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vilanterol"
]
],
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vilanterol"
]
]
] |
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Midostaurin may lead to a major life threatening interaction when taken with Tucatinib and Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Midostaurin may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Midostaurin may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Midostaurin may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Vilanterol
Midostaurin may lead to a major life threatening interaction when taken with Sotalol and Sotalol may lead to a major life threatening interaction when taken with Vilanterol
|
DB01177
|
DB10583
| 77
| 949
|
[
"DDInter904",
"DDInter415"
] |
Idarubicin
|
Clostridium tetani toxoid antigen (formaldehyde inactivated)
|
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
|
Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium sulfate filtration and precipation.
|
Moderate
| 1
|
[
[
[
77,
24,
949
]
],
[
[
77,
64,
550
],
[
550,
24,
949
]
],
[
[
77,
63,
589
],
[
589,
24,
949
]
],
[
[
77,
25,
1259
],
[
1259,
63,
949
]
],
[
[
77,
24,
1683
],
[
1683,
24,
949
]
],
[
[
77,
25,
478
],
[
478,
24,
949
]
],
[
[
77,
24,
1619
],
[
1619,
63,
949
]
],
[
[
77,
74,
51
],
[
51,
24,
949
]
],
[
[
77,
64,
550
],
[
550,
25,
1377
],
[
1377,
24,
949
]
],
[
[
77,
63,
589
],
[
589,
25,
1377
],
[
1377,
24,
949
]
]
] |
[
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab"
],
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Idarubicin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab"
],
[
"Trastuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
]
] |
Idarubicin may lead to a major life threatening interaction when taken with Trastuzumab and Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Idarubicin may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Idarubicin may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Idarubicin (Compound) resembles Daunorubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Idarubicin may lead to a major life threatening interaction when taken with Trastuzumab and Trastuzumab may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
|
DB00191
|
DB01309
| 73
| 1,254
|
[
"DDInter1447",
"DDInter933"
] |
Phentermine
|
Insulin glulisine
|
Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows this agent to be classified under the Schedule IV drugs (low abuse potential). Phentermine was FDA approved for short-term weight management in 1959 and it became widely used in 1960. This initial product, formed by the combination of phentermine with [fenfluramine] and [dexfenfluramine] was discontinued after finding several reports of abnormal valves in nearly 30% of the consumers.[A174376, T403] Later on, phentermine was approved alone and in combination with topiramate in 2012 as a new alternative that required lower doses of phentermine to
|
Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin glulisine, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after trying several oral medications such as , , or have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. Marketed as the brand name product Apidra, insulin glulisine begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. Due to its duration of action of around 5 hours, Apidra is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting "basal insulin" such as , , and to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia. Insulin glulisine is a biosynthetic, rapid-acting human insulin analogue produced in a non-pathogenic laboratory strain of _Escherichia coli_ (K12). This recombinant hormone differs from native human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine at position B29 is replaced by glutamic acid. These structural modifications decrease hexamer formation, stabilize insulin glulisine monomers and increase the rate of absorption and onset of action compared to human insulin. Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.
|
Moderate
| 1
|
[
[
[
73,
24,
1254
]
],
[
[
73,
35,
280
],
[
280,
63,
1254
]
],
[
[
73,
24,
1645
],
[
1645,
24,
1254
]
],
[
[
73,
36,
1529
],
[
1529,
63,
1254
]
],
[
[
73,
25,
341
],
[
341,
63,
1254
]
],
[
[
73,
24,
1450
],
[
1450,
63,
1254
]
],
[
[
73,
36,
1161
],
[
1161,
24,
1254
]
],
[
[
73,
25,
758
],
[
758,
24,
1254
]
],
[
[
73,
64,
529
],
[
529,
24,
1254
]
],
[
[
73,
35,
280
],
[
280,
63,
1645
],
[
1645,
24,
1254
]
]
] |
[
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Phentermine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephentermine"
],
[
"Mephentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Phentermine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Metamfetamine"
],
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phendimetrazine"
],
[
"Phendimetrazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Phentermine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Selegiline"
],
[
"Selegiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Phentermine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephentermine"
],
[
"Mephentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
]
] |
Phentermine (Compound) resembles Mephentermine (Compound) and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine and Me
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Phentermine (Compound) resembles Metamfetamine (Compound) and Phentermine may lead to a major life threatening interaction when taken with Metamfetamine and Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Phentermine may lead to a major life threatening interaction when taken with Phendimetrazine and Phendimetrazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Phentermine (Compound) resembles Selegiline (Compound) and Phentermine may lead to a major life threatening interaction when taken with Selegiline and Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Phentermine may lead to a major life threatening interaction when taken with Fluoxetine and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Phentermine may lead to a major life threatening interaction when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Phentermine (Compound) resembles Mephentermine (Compound) and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine and Mephentermine may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
|
DB00196
|
DB09054
| 600
| 384
|
[
"DDInter743",
"DDInter905"
] |
Fluconazole
|
Idelalisib
|
Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.
|
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
|
Moderate
| 1
|
[
[
[
600,
24,
384
]
],
[
[
600,
23,
222
],
[
222,
23,
384
]
],
[
[
600,
25,
318
],
[
318,
23,
384
]
],
[
[
600,
23,
1627
],
[
1627,
62,
384
]
],
[
[
600,
25,
1618
],
[
1618,
24,
384
]
],
[
[
600,
63,
305
],
[
305,
24,
384
]
],
[
[
600,
24,
891
],
[
891,
24,
384
]
],
[
[
600,
24,
242
],
[
242,
63,
384
]
],
[
[
600,
23,
1101
],
[
1101,
24,
384
]
],
[
[
600,
23,
466
],
[
466,
63,
384
]
]
] |
[
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
]
] |
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Fluconazole may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Fluconazole may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
|
DB01242
|
DB01246
| 1,237
| 820
|
[
"DDInter410",
"DDInter45"
] |
Clomipramine
|
Alimemazine
|
Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic ser
|
A phenothiazine derivative that is used as an antipruritic.
|
Moderate
| 1
|
[
[
[
1237,
24,
820
]
],
[
[
1237,
63,
104
],
[
104,
40,
820
]
],
[
[
1237,
1,
11275
],
[
11275,
40,
820
]
],
[
[
1237,
63,
401
],
[
401,
24,
820
]
],
[
[
1237,
40,
11294
],
[
11294,
1,
820
]
],
[
[
1237,
24,
649
],
[
649,
1,
820
]
],
[
[
1237,
6,
8374
],
[
8374,
45,
820
]
],
[
[
1237,
21,
28662
],
[
28662,
60,
820
]
],
[
[
1237,
62,
112
],
[
112,
23,
820
]
],
[
[
1237,
24,
1342
],
[
1342,
63,
820
]
]
] |
[
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Alimemazine"
]
],
[
[
"Clomipramine",
"{u} (Compound) resembles {v} (Compound)",
"Chlorprothixene"
],
[
"Chlorprothixene",
"{u} (Compound) resembles {v} (Compound)",
"Alimemazine"
]
],
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Clomipramine",
"{u} (Compound) resembles {v} (Compound)",
"Pipotiazine"
],
[
"Pipotiazine",
"{u} (Compound) resembles {v} (Compound)",
"Alimemazine"
]
],
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} (Compound) resembles {v} (Compound)",
"Alimemazine"
]
],
[
[
"Clomipramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Alimemazine"
]
],
[
[
"Clomipramine",
"{u} (Compound) causes {v} (Side Effect)",
"Tremor"
],
[
"Tremor",
"{u} (Side Effect) is caused by {v} (Compound)",
"Alimemazine"
]
],
[
[
"Clomipramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alimemazine"
]
],
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
],
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
]
] |
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Clomipramine (Compound) resembles Chlorprothixene (Compound) and Chlorprothixene (Compound) resembles Alimemazine (Compound)
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Clomipramine (Compound) resembles Pipotiazine (Compound) and Pipotiazine (Compound) resembles Alimemazine (Compound)
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Alimemazine (Compound)
Clomipramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alimemazine (Compound)
Clomipramine (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Alimemazine (Compound)
Clomipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Alimemazine
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
|
DB00069
|
DB00609
| 367
| 595
|
[
"DDInter946",
"DDInter694"
] |
Interferon alfacon-1
|
Ethionamide
|
Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional amino acid changes were made to facilitate the molecular construction, and a corresponding synthetic DNA sequence was constructed using chemical synthesis methodology. Interferon alfacon-1 differs from interferon alfa-2b at 20/166 amino acids (88% homology), and comparison with interferon-beta shows identity at over 30% of the amino acid positions. Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. Prior to final purification, Interferon alfacon-
|
A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868)
|
Moderate
| 1
|
[
[
[
367,
24,
595
]
],
[
[
367,
24,
372
],
[
372,
63,
595
]
],
[
[
367,
63,
1057
],
[
1057,
24,
595
]
],
[
[
367,
24,
597
],
[
597,
24,
595
]
],
[
[
367,
25,
1510
],
[
1510,
64,
595
]
],
[
[
367,
24,
372
],
[
372,
21,
28787
],
[
28787,
60,
595
]
],
[
[
367,
63,
1057
],
[
1057,
25,
372
],
[
372,
63,
595
]
],
[
[
367,
24,
1662
],
[
1662,
63,
597
],
[
597,
24,
595
]
],
[
[
367,
24,
597
],
[
597,
18,
4360
],
[
4360,
57,
595
]
],
[
[
367,
24,
112
],
[
112,
7,
16981
],
[
16981,
46,
595
]
]
] |
[
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethionamide"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethionamide"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethionamide"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethionamide"
]
],
[
[
"Interferon alfacon-1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ethionamide"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ethionamide"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethionamide"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethionamide"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} (Compound) downregulates {v} (Gene)",
"TIMM9"
],
[
"TIMM9",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ethionamide"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} (Compound) upregulates {v} (Gene)",
"ZNF586"
],
[
"ZNF586",
"{u} (Gene) is upregulated by {v} (Compound)",
"Ethionamide"
]
]
] |
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Ethionamide
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Ethionamide
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ethionamide
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Ethionamide
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Ethionamide (Compound)
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Ethionamide
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ethionamide
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Ethionamide (Compound)
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole (Compound) upregulates ZNF586 (Gene) and ZNF586 (Gene) is upregulated by Ethionamide (Compound)
|
DB00554
|
DB01082
| 1,027
| 1,448
|
[
"DDInter1478",
"DDInter1713"
] |
Piroxicam
|
Streptomycin
|
A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily.
|
Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity.[A233325,A232294] Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.
|
Moderate
| 1
|
[
[
[
1027,
24,
1448
]
],
[
[
1027,
6,
10612
],
[
10612,
45,
1448
]
],
[
[
1027,
24,
1272
],
[
1272,
63,
1448
]
],
[
[
1027,
63,
91
],
[
91,
24,
1448
]
],
[
[
1027,
24,
1479
],
[
1479,
24,
1448
]
],
[
[
1027,
40,
1171
],
[
1171,
24,
1448
]
],
[
[
1027,
25,
1552
],
[
1552,
64,
1448
]
],
[
[
1027,
25,
629
],
[
629,
25,
1448
]
],
[
[
1027,
24,
416
],
[
416,
74,
1448
]
],
[
[
1027,
6,
10612
],
[
10612,
45,
59
],
[
59,
24,
1448
]
]
] |
[
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Piroxicam",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compound)",
"Streptomycin"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
],
[
"Flucytosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vancomycin"
],
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Piroxicam",
"{u} (Compound) resembles {v} (Compound)",
"Meloxicam"
],
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Piroxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
],
[
"Ioversol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Streptomycin"
]
],
[
[
"Piroxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Streptomycin"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
],
[
"Kanamycin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Piroxicam",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compound)",
"Etodolac"
],
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
]
] |
Piroxicam (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Streptomycin (Compound)
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine and Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Piroxicam (Compound) resembles Meloxicam (Compound) and Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Piroxicam may lead to a major life threatening interaction when taken with Ioversol and Ioversol may lead to a major life threatening interaction when taken with Streptomycin
Piroxicam may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Streptomycin
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin (Compound) resembles Streptomycin (Compound) and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Piroxicam (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Etodolac (Compound) and Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
|
DB00373
|
DB08881
| 461
| 868
|
[
"DDInter1809",
"DDInter1925"
] |
Timolol
|
Vemurafenib
|
Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
|
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
|
Moderate
| 1
|
[
[
[
461,
24,
868
]
],
[
[
461,
6,
12523
],
[
12523,
45,
868
]
],
[
[
461,
7,
6952
],
[
6952,
46,
868
]
],
[
[
461,
21,
28847
],
[
28847,
60,
868
]
],
[
[
461,
63,
608
],
[
608,
23,
868
]
],
[
[
461,
23,
578
],
[
578,
24,
868
]
],
[
[
461,
25,
480
],
[
480,
24,
868
]
],
[
[
461,
24,
760
],
[
760,
63,
868
]
],
[
[
461,
23,
286
],
[
286,
63,
868
]
],
[
[
461,
24,
1220
],
[
1220,
24,
868
]
]
] |
[
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Timolol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Timolol",
"{u} (Compound) upregulates {v} (Gene)",
"MCOLN1"
],
[
"MCOLN1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Timolol",
"{u} (Compound) causes {v} (Side Effect)",
"Eye disorder"
],
[
"Eye disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vemurafenib"
]
],
[
[
"Timolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Timolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Timolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
]
] |
Timolol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Vemurafenib (Compound)
Timolol (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Vemurafenib (Compound)
Timolol (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Timolol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Timolol may lead to a major life threatening interaction when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Timolol may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
|
DB00250
|
DB00526
| 10
| 1,555
|
[
"DDInter475",
"DDInter1355"
] |
Dapsone
|
Oxaliplatin
|
A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)
|
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The DACH moiety also prevents cross-resistance with cisplatin and carboplatin. Although oxaliplatin has been investigated as a monotherapy, it is typically administered in combination with fluorouracil and leucovorin, known as the FOLFOX regimen, for the treatment of colorectal cancer.[A796,A797] This is an effective combination treatment both as a first-line treatment and in patients refractory to an initial fluorouracil and leucovorin combination. Ongoing trials have also shown promising results for oxaliplatin use in nonHodgkin’s lymphoma, breast cancer, mesothelioma, and non-small cell lung cancer. Oxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin®.
|
Moderate
| 1
|
[
[
[
10,
24,
1555
]
],
[
[
10,
6,
9375
],
[
9375,
45,
1555
]
],
[
[
10,
1,
1247
],
[
1247,
62,
1555
]
],
[
[
10,
24,
289
],
[
289,
24,
1555
]
],
[
[
10,
24,
231
],
[
231,
63,
1555
]
],
[
[
10,
63,
1451
],
[
1451,
24,
1555
]
],
[
[
10,
25,
1292
],
[
1292,
64,
1555
]
],
[
[
10,
24,
908
],
[
908,
64,
1555
]
],
[
[
10,
25,
695
],
[
695,
25,
1555
]
],
[
[
10,
63,
581
],
[
581,
25,
1555
]
]
] |
[
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Dapsone",
"{u} (Compound) binds {v} (Gene)",
"MPO"
],
[
"MPO",
"{u} (Gene) is bound by {v} (Compound)",
"Oxaliplatin"
]
],
[
[
"Dapsone",
"{u} (Compound) resembles {v} (Compound)",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cerivastatin"
],
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stavudine"
],
[
"Stavudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfa-n1"
],
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Dapsone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Dapsone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
]
]
] |
Dapsone (Compound) binds MPO (Gene) and MPO (Gene) is bound by Oxaliplatin (Compound)
Dapsone (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Oxaliplatin
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin and Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Stavudine and Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfa-n1 and Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Dapsone may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Oxaliplatin
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Oxaliplatin
Dapsone may lead to a major life threatening interaction when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Oxaliplatin
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Oxaliplatin
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.